{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:15:35Z","timestamp":1787652935014,"version":"build-2736575974"},"reference-count":826,"publisher":"National Institute for Health and Care Research","issue":"66","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["14\/151\/08"],"award-info":[{"award-number":["14\/151\/08"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background<\/jats:title>\n Rheumatoid arthritis (RA) is a chronic, debilitating disease associated with reduced quality of life and substantial costs. It is unclear which tests and assessment tools allow the best assessment of prognosis in people with early RA and whether or not variables predict the response of patients to different drug treatments.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To systematically review evidence on the use of selected tests and assessment tools in patients with early RA (1) in the evaluation of a prognosis (review 1) and (2) as predictive markers of treatment response (review 2).<\/jats:p>\n <\/jats:sec>\n \n Data sources<\/jats:title>\n Electronic databases (e.g. MEDLINE, EMBASE, The Cochrane Library, Web of Science Conference Proceedings; searched to September 2016), registers, key websites, hand-searching of reference lists of included studies and key systematic reviews and contact with experts.<\/jats:p>\n <\/jats:sec>\n \n Study selection<\/jats:title>\n Review 1 \u2013 primary studies on the development, external validation and impact of clinical prediction models for selected outcomes in adult early RA patients. Review 2 \u2013 primary studies on the interaction between selected baseline covariates and treatment (conventional and biological disease-modifying antirheumatic drugs) on salient outcomes in adult early RA patients.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Review 1 \u2013 22 model development studies and one combined model development\/external validation study reporting 39 clinical prediction models were included. Five external validation studies evaluating eight clinical prediction models for radiographic joint damage were also included.\n c<\/jats:italic>\n -statistics from internal validation ranged from 0.63 to 0.87 for radiographic progression (different definitions, six studies) and 0.78 to 0.82 for the Health Assessment Questionnaire (HAQ). Predictive performance in external validations varied considerably. Three models [(1) Active controlled Study of Patients receiving Infliximab for the treatment of Rheumatoid arthritis of Early onset (ASPIRE) C-reactive protein (ASPIRE CRP), (2) ASPIRE erythrocyte sedimentation rate (ASPIRE ESR) and (3) Behandelings Strategie (BeSt)] were externally validated using the same outcome definition in more than one population. Results of the random-effects meta-analysis suggested substantial uncertainty in the expected predictive performance of models in a new sample of patients. Review 2 \u2013 12 studies were identified. Covariates examined included anti-citrullinated protein\/peptide anti-body (ACPA) status, smoking status, erosions, rheumatoid factor status, C-reactive protein level, erythrocyte sedimentation rate, swollen joint count (SJC), body mass index and vascularity of synovium on power Doppler ultrasound (PDUS). Outcomes examined included erosions\/radiographic progression, disease activity, physical function and Disease Activity Score-28 remission. There was statistical evidence to suggest that ACPA status, SJC and PDUS status at baseline may be treatment effect modifiers, but not necessarily that they are prognostic of response for all treatments. Most of the results were subject to considerable uncertainty and were not statistically significant.\n <\/jats:p>\n <\/jats:sec>\n \n Limitations<\/jats:title>\n The meta-analysis in review 1 was limited by the availability of only a small number of external validation studies. Studies rarely investigated the interaction between predictors and treatment.<\/jats:p>\n <\/jats:sec>\n \n Suggested research priorities<\/jats:title>\n Collaborative research (including the use of individual participant data) is needed to further develop and externally validate the clinical prediction models. The clinical prediction models should be validated with respect to individual treatments. Future assessments of treatment by covariate interactions should follow good statistical practice.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Review 1 \u2013 uncertainty remains over the optimal prediction model(s) for use in clinical practice. Review 2 \u2013 in general, there was insufficient evidence that the effect of treatment depended on baseline characteristics.<\/jats:p>\n <\/jats:sec>\n \n Study registration<\/jats:title>\n This study is registered as PROSPERO CRD42016042402.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n The National Institute for Health Research Health Technology Assessment programme.<\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/hta22660","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T05:50:22Z","timestamp":1543816222000},"page":"1-294","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":23,"title":["Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews"],"prefix":"10.3310","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0704-4762","authenticated-orcid":true,"given":"Rachel","family":"Archer","sequence":"first","affiliation":[{"name":"School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8617-8875","authenticated-orcid":true,"given":"Emma","family":"Hock","sequence":"additional","affiliation":[{"name":"School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3326-9842","authenticated-orcid":true,"given":"Jean","family":"Hamilton","sequence":"additional","affiliation":[{"name":"School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9867-7209","authenticated-orcid":true,"given":"John","family":"Stevens","sequence":"additional","affiliation":[{"name":"School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2397-402X","authenticated-orcid":true,"given":"Munira","family":"Essat","sequence":"additional","affiliation":[{"name":"School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6549-5081","authenticated-orcid":true,"given":"Edith","family":"Poku","sequence":"additional","affiliation":[{"name":"School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5582-9946","authenticated-orcid":true,"given":"Mark","family":"Clowes","sequence":"additional","affiliation":[{"name":"School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2552-5260","authenticated-orcid":true,"given":"Abdullah","family":"Pandor","sequence":"additional","affiliation":[{"name":"School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3099-9877","authenticated-orcid":true,"given":"Matt","family":"Stevenson","sequence":"additional","affiliation":[{"name":"School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2018,11]]},"reference":[{"key":"key20181204135736878_ref1-bib1","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.berh.2007.05.006","article-title":"The course of established rheumatoid arthritis","volume":"21","author":"Scott","year":"2007","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"key20181204135736878_ref1-bib2","first-page":"636","article-title":"Early radiographic joint space narrowing and erosion and later malalignment in rheumatoid arthritis: a longitudinal analysis","volume":"25","author":"Pincus","year":"1998","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib3","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1093\/rheumatology\/39.9.998","article-title":"Radiographic damage of large joints in long-term rheumatoid arthritis and its relation to function","volume":"39","author":"Drossaers-Bakker","year":"2000","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/art.24281","article-title":"Current risk factors for work disability associated with rheumatoid arthritis: recent data from a US national cohort","volume":"61","author":"Allaire","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib5","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.berh.2007.05.003","article-title":"Mortality in established rheumatoid arthritis","volume":"21","author":"Naz","year":"2007","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"key20181204135736878_ref1-bib6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jbspin.2012.02.005","article-title":"Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis","volume":"80","author":"Dadoun","year":"2013","journal-title":"Joint Bone Spine"},{"key":"key20181204135736878_ref1-bib7","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1093\/rheumatology\/kep252","article-title":"Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies","volume":"48","author":"Meune","year":"2009","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib8","volume-title":"Rheumatoid Arthritis: National Clinical Guideline for Management and Treatment in Adults","author":"National Collaborating Centre for Chronic Conditions","year":"2009"},{"key":"key20181204135736878_ref1-bib9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1093\/rheumatology\/33.8.735","article-title":"The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register","volume":"33","author":"Symmons","year":"1994","journal-title":"Br J Rheumatol"},{"key":"key20181204135736878_ref1-bib10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/1529-0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B","article-title":"Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins","volume":"43","author":"MacGregor","year":"2000","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1136\/ard.55.2.89","article-title":"Occurrence of rheumatoid arthritis is not increased in the first degree relatives of a population based inception cohort of inflammatory polyarthritis","volume":"55","author":"Jones","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib12","doi-asserted-by":"publisher","first-page":"i87","DOI":"10.1093\/rheumatology\/keu101.006","article-title":"Final 5-year safety and efficacy results of a phase 3, randomized, placebo-controlled trial of golimumab in patients with active rheumatoid arthritis despite previous anti-tumor necrosis factor therapy","volume":"53","author":"Smolen","year":"2014","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib13","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib14","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib15","first-page":"S63","article-title":"Radiographic progression in rheumatoid arthritis","volume":"23","author":"Landewe","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"key20181204135736878_ref1-bib16","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1177\/028418517701800415","article-title":"Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films","volume":"18","author":"Larsen","year":"1977","journal-title":"Acta Radiol Diagn"},{"key":"key20181204135736878_ref1-bib17","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/art.1780140605","article-title":"Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities","volume":"14","author":"Sharp","year":"1971","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib18","first-page":"261","article-title":"How to read radiographs according to the Sharp\/van der Heijde method","volume":"27","author":"van der Heijde","year":"2000","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib20","first-page":"S14","article-title":"The Health Assessment Questionnaire (HAQ)","volume":"23","author":"Bruce","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"key20181204135736878_ref1-bib21","doi-asserted-by":"publisher","first-page":"e5595","DOI":"10.1136\/bmj.e5595","article-title":"Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes","volume":"346","author":"Hemingway","year":"2013","journal-title":"BMJ"},{"key":"key20181204135736878_ref1-bib22","doi-asserted-by":"publisher","first-page":"e1001380","DOI":"10.1371\/journal.pmed.1001380","article-title":"Prognosis Research Strategy (PROGRESS) 2: prognostic factor research","volume":"10","author":"Riley","year":"2013","journal-title":"PLOS Med"},{"key":"key20181204135736878_ref1-bib23","doi-asserted-by":"publisher","first-page":"e1001381","DOI":"10.1371\/journal.pmed.1001381","article-title":"Prognosis Research Strategy (PROGRESS) 3: prognostic model research","volume":"10","author":"Steyerberg","year":"2013","journal-title":"PLOS Med"},{"key":"key20181204135736878_ref1-bib24","doi-asserted-by":"publisher","first-page":"e5793","DOI":"10.1136\/bmj.e5793","article-title":"Prognosis research strategy (PROGRESS) 4: stratified medicine research","volume":"346","author":"Hingorani","year":"2013","journal-title":"BMJ"},{"key":"key20181204135736878_ref1-bib25","doi-asserted-by":"publisher","first-page":"c6244","DOI":"10.1136\/bmj.c6244","article-title":"How should we balance individual and population benefits of statins for preventing cardiovascular disease?","volume":"342","author":"Hingorani","year":"2010","journal-title":"BMJ"},{"key":"key20181204135736878_ref1-bib26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.7326\/M14-0697","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement","volume":"162","author":"Collins","year":"2015","journal-title":"Ann Intern Med"},{"key":"key20181204135736878_ref1-bib27","doi-asserted-by":"publisher","first-page":"b375","DOI":"10.1136\/bmj.b375","article-title":"Prognosis and prognostic research: what, why, and how?","volume":"338","author":"Moons","year":"2009","journal-title":"BMJ"},{"key":"key20181204135736878_ref1-bib28","doi-asserted-by":"publisher","first-page":"b606","DOI":"10.1136\/bmj.b606","article-title":"Prognosis and prognostic research: application and impact of prognostic models in clinical practice","volume":"338","author":"Moons","year":"2009","journal-title":"BMJ"},{"key":"key20181204135736878_ref1-bib29","doi-asserted-by":"publisher","first-page":"b604","DOI":"10.1136\/bmj.b604","article-title":"Prognosis and prognostic research: developing a prognostic model","volume":"338","author":"Royston","year":"2009","journal-title":"BMJ"},{"key":"key20181204135736878_ref1-bib30","doi-asserted-by":"publisher","first-page":"b605","DOI":"10.1136\/bmj.b605","article-title":"Prognosis and prognostic research: validating a prognostic model","volume":"338","author":"Altman","year":"2009","journal-title":"BMJ"},{"key":"key20181204135736878_ref1-bib31","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1136\/heartjnl-2011-301246","article-title":"Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker","volume":"98","author":"Moons","year":"2012","journal-title":"Heart"},{"key":"key20181204135736878_ref1-bib32","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S0895-4356(96)00236-3","article-title":"A simulation study of the number of events per variable in logistic regression analysis","volume":"49","author":"Peduzzi","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"key20181204135736878_ref1-bib33","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3462-1","volume-title":"Regression Modelling Strategies with Applications to Linear Models, Logistic Regression and Survival Analysis","author":"Harrell","year":"2001"},{"key":"key20181204135736878_ref1-bib34","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"key":"key20181204135736878_ref1-bib35","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/sim.2331","article-title":"Dichotomizing continuous predictors in multiple regression: a bad idea","volume":"25","author":"Royston","year":"2006","journal-title":"Stat Med"},{"key":"key20181204135736878_ref1-bib36","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/jnci\/86.11.829","article-title":"Dangers of using \u2018optimal\u2019 cutpoints in the evaluation of prognostic factors","volume":"86","author":"Altman","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"key20181204135736878_ref1-bib37","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat Med"},{"key":"key20181204135736878_ref1-bib38","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/0272989X0102100106","article-title":"Prognostic modeling with logistic regression analysis: in search of a sensible strategy in small data sets","volume":"21","author":"Steyerberg","year":"2001","journal-title":"Med Decis Making"},{"key":"key20181204135736878_ref1-bib39","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/biomet\/78.3.691","article-title":"A note on a general definition of the coefficient of determination","volume":"78","author":"Nagelkerke","year":"1991","journal-title":"Biometrika"},{"key":"key20181204135736878_ref1-bib40","doi-asserted-by":"publisher","first-page":"i6460","DOI":"10.1136\/bmj.i6460","article-title":"A guide to systematic review and meta-analysis of prediction model performance","volume":"356","author":"Debray","year":"2017","journal-title":"BMJ"},{"key":"key20181204135736878_ref1-bib41","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1471-2288-14-40","article-title":"External validation of multivariable prediction models: a systematic review of methodological conduct and reporting","volume":"14","author":"Collins","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"key20181204135736878_ref1-bib42","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1093\/aje\/kwq223","article-title":"External validity of risk models: use of benchmark values to disentangle a case-mix effect from incorrect coefficients","volume":"172","author":"Vergouwe","year":"2010","journal-title":"Am J Epidemiol"},{"key":"key20181204135736878_ref1-bib43","volume-title":"Biostatistics for Biomedical Research","author":"Harrell","year":"2017"},{"key":"key20181204135736878_ref1-bib44","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1741-7015-2-23","article-title":"Developing optimal search strategies for detecting clinically sound prognostic studies in MEDLINE: an analytic survey","volume":"2","author":"Wilczynski","year":"2004","journal-title":"BMC Med"},{"key":"key20181204135736878_ref1-bib45","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1017\/S0266462315000112","article-title":"Iterative sifting in the selection of research evidence: implications for reviews and other decision problems","volume":"31","author":"Archer","year":"2015","journal-title":"Int J Technol Assess Health Care"},{"key":"key20181204135736878_ref1-bib46","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1136\/annrheumdis-2011-200343","article-title":"The relationship between joint damage and functional disability in rheumatoid arthritis: a systematic review","volume":"71","author":"Bombardier","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib47","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1093\/rheumatology\/kev108","article-title":"Quality indicators in rheumatoid arthritis: results from the METEOR database","volume":"54","author":"Navarro-Comp\u00e1n","year":"2015","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib48","doi-asserted-by":"publisher","first-page":"e1001744","DOI":"10.1371\/journal.pmed.1001744","article-title":"Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist","volume":"11","author":"Moons","year":"2014","journal-title":"PLOS Med"},{"key":"key20181204135736878_ref1-bib49","unstructured":"Wolff RF, Moons KGM, Riley RD, Whiting PF, Westwood M, Collins G, et al. PROBAST \u2013 A Risk-Of-Bias Tool for Prediction-Modelling Studies. Abstracts of the Global Evidence Summit, Cape Town, South Africa. Cochrane Database of Systematic Reviews 2017;9(Suppl. 1)."},{"key":"key20181204135736878_ref1-bib50","volume-title":"R: A Language and Environment for Statistical Computing","author":"R-Development Core Team","year":"2004"},{"key":"key20181204135736878_ref1-bib51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"key":"key20181204135736878_ref1-bib52","doi-asserted-by":"publisher","DOI":"10.1177\/0962280217705678","article-title":"Meta-analysis of prediction model performance across multiple studies: which scale helps ensure between-study normality for the C-statistic and calibration measures?","volume":"27","author":"Snell","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"key20181204135736878_ref1-bib53","first-page":"728","article-title":"Developing optimal search strategies for detecting sound clinical prediction studies in MEDLINE","author":"Wong","year":"2003","journal-title":"AMIA Annu Symp Proc"},{"key":"key20181204135736878_ref1-bib54","doi-asserted-by":"publisher","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"key20181204135736878_ref1-bib55","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLOS Med"},{"key":"key20181204135736878_ref1-bib56","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/art.10513","article-title":"Long-term outcome in rheumatoid arthritis: a simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup","volume":"47","author":"Drossaers-Bakker","year":"2002","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib57","first-page":"1281","article-title":"A risk model for the prediction of radiographic progression: results from SONORA study","volume":"61","author":"Bombardier","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib58","first-page":"1503","article-title":"A prognostic model for functional outcome in early rheumatoid arthritis","volume":"33","author":"Bansback","year":"2006","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib59","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1136\/ard.2005.041376","article-title":"Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset","volume":"65","author":"Berglin","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib60","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1136\/bmj.313.7055.471","article-title":"A simple algorithm to predict the development of radiological erosions in patients with early rheumatoid arthritis: prospective cohort study","volume":"313","author":"Brennan","year":"1996","journal-title":"BMJ"},{"key":"key20181204135736878_ref1-bib61","doi-asserted-by":"publisher","first-page":"e60635","DOI":"10.1371\/journal.pone.0060635","article-title":"Development of a multi-biomarker disease activity test for rheumatoid arthritis","volume":"8","author":"Centola","year":"2013","journal-title":"PLOS ONE"},{"key":"key20181204135736878_ref1-bib62","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1002\/1529-0131(200108)44:8<1736::AID-ART308>3.0.CO;2-I","article-title":"Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study","volume":"44","author":"Combe","year":"2001","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib63","first-page":"2344","article-title":"Predictive factors of 5-year health assessment questionnaire disability in early rheumatoid arthritis","volume":"30","author":"Combe","year":"2003","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib64","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3899\/jrheum.140327","article-title":"A simplified baseline prediction model for joint damage progression in rheumatoid arthritis: a step toward personalized medicine","volume":"42","author":"de Punder","year":"2015","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib65","first-page":"1747","article-title":"Using predicted disease outcome to provide differentiated treatment of early rheumatoid arthritis","volume":"33","author":"de Vries-Bouwstra","year":"2006","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib66","doi-asserted-by":"publisher","first-page":"e000180","DOI":"10.1136\/rmdopen-2015-000180","article-title":"Predictive value of autoantibodies from anti-CCP2, anti-MCV and anti-human citrullinated fibrinogen tests, in early rheumatoid arthritis patients with rapid radiographic progression at 1 year: results from the ESPOIR cohort","volume":"1","author":"Degbo\u00e9","year":"2015","journal-title":"RMD Open"},{"key":"key20181204135736878_ref1-bib67","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3109\/03009742.2011.594964","article-title":"Towards personalized treatment: predictors of short-term HAQ response in recent-onset active rheumatoid arthritis are different from predictors of rapid radiological progression","volume":"41","author":"Dirven","year":"2012","journal-title":"Scand J Rheumatol"},{"key":"key20181204135736878_ref1-bib68","first-page":"48","article-title":"Study. Is it possible to predict radiological damage in early rheumatoid arthritis (RA)? A report on the occurrence, progression, and prognostic factors of radiological erosions over the first 3 years in 866 patients from the Early RA Study (ERAS)","volume":"69","author":"Dixey","year":"2004","journal-title":"J Rheumatol Suppl"},{"key":"key20181204135736878_ref1-bib69","doi-asserted-by":"publisher","first-page":"R249","DOI":"10.1186\/ar4092","article-title":"Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort","volume":"14","author":"Fautrel","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"key20181204135736878_ref1-bib70","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1136\/ard.2003.014233","article-title":"Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP)","volume":"63","author":"Forslind","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib71","first-page":"284","article-title":"Disability measured by the modified health assessment questionnaire in early rheumatoid arthritis: prognostic factors after two years of follow-up","volume":"27","author":"Graell","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"key20181204135736878_ref1-bib72","doi-asserted-by":"publisher","first-page":"R30","DOI":"10.1186\/ar3734","article-title":"Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up","volume":"14","author":"Houseman","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"key20181204135736878_ref1-bib73","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1136\/annrheumdis-2013-204601","article-title":"Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial","volume":"74","author":"Saevarsdottir","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib74","unstructured":"Saevarsdottir S, Forslind K, Albertsson K, Rezaei H, Engstrom A, Geborek P, et al. Development of a Matrix Risk Model to Predict Rapid Radiographic Progression in Early Rheumatoid Arthritis. Results from a Randomized Trial Population. American College of Rheumatology\/Association of Rheumatology Health Professionals (ACR\/ARHP) Annual Scientific Meeting, Chicago, IL, 4\u20139 November 2011."},{"key":"key20181204135736878_ref1-bib75","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s10067-006-0462-4","article-title":"Prognostic factors of radiographic progression in early rheumatoid arthritis: a two year prospective study after a structured therapeutic strategy using DMARDs and very low doses of glucocorticoids","volume":"26","author":"Sanmart\u00ed","year":"2007","journal-title":"Clin Rheumatol"},{"key":"key20181204135736878_ref1-bib76","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1136\/ard.2006.068247","article-title":"High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study","volume":"67","author":"Syversen","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib77","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1136\/annrheumdis-2013-204277","article-title":"Predicting the severity of joint damage in rheumatoid arthritis; the contribution of genetic factors","volume":"74","author":"van Steenbergen","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib78","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1093\/rheumatology\/kep155","article-title":"A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis","volume":"48","author":"Vastesaeger","year":"2009","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib79","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1136\/ard.2009.121160","article-title":"A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study","volume":"69","author":"Visser","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib80","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.semarthrit.2013.09.004","article-title":"The performance of matrices in daily clinical practice to predict rapid radiologic progression in patients with early RA","volume":"43","author":"De Cock","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib81","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/rheumatology\/kem288","article-title":"Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis","volume":"47","author":"Verschueren","year":"2008","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib82","doi-asserted-by":"publisher","first-page":"e000245","DOI":"10.1136\/rmdopen-2016-000245","article-title":"Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data","volume":"2","author":"Granger","year":"2016","journal-title":"RMD Open"},{"key":"key20181204135736878_ref1-bib83","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1136\/annrheumdis-2013-204986","article-title":"Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial","volume":"74","author":"Hambardzumyan","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib84","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10067-014-2815-8","article-title":"Can we prevent rapid radiological progression in patients with early rheumatoid arthritis?","volume":"34","author":"Heimans","year":"2015","journal-title":"Clin Rheumatol"},{"key":"key20181204135736878_ref1-bib85","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.3899\/jrheum.131412","article-title":"A multibiomarker disease activity score for rheumatoid arthritis predicts radiographic joint damage in the BeSt study","volume":"41","author":"Markusse","year":"2014","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib86","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1136\/ard.2010.135319","article-title":"Effectiveness of initial treatment allocation based on expert opinion for prevention of rapid radiographic progression in daily practice of an early RA cohort","volume":"70","author":"Durnez","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib87","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial","volume":"50","author":"St Clair","year":"2004","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib88","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"key20181204135736878_ref1-bib89","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1002\/art.21405","article-title":"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial","volume":"52","author":"Goekoop-Ruiterman","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib90","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S0140-6736(09)60944-2","article-title":"Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (SWEFOT trial): 1-year results of a randomised trial","volume":"374","author":"van Vollenhoven","year":"2009","journal-title":"Lancet"},{"key":"key20181204135736878_ref1-bib91","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1136\/annrheumdis-2013-203243","article-title":"A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study","volume":"73","author":"Heimans","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib92","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1021\/jm0611004","article-title":"Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2)","volume":"50","author":"Anderson","year":"2007","journal-title":"J Med Chem"},{"key":"key20181204135736878_ref1-bib93","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1002\/sim.3603","article-title":"Measurement in clinical trials: a neglected issue for statisticians?","volume":"28","author":"Senn","year":"2009","journal-title":"Stat Med"},{"key":"key20181204135736878_ref1-bib94","first-page":"S755","article-title":"Matrix risk model for prediction of rapid radiographic progression in rheumatoid arthritis","volume":"58","author":"Vastesaeger","year":"2008","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib95","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/acr.21870","article-title":"Performance of matrix-based risk models for rapid radiographic progression in a cohort of patients with established rheumatoid arthritis","volume":"65","author":"Lillegraven","year":"2013","journal-title":"Arthritis Care Res"},{"key":"key20181204135736878_ref1-bib96","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1093\/ije\/dyq063","article-title":"Statistical methods for the time-to-event analysis of individual participant data from multiple epidemiological studies","volume":"39","author":"Thompson","year":"2010","journal-title":"Int J Epidemiol"},{"key":"key20181204135736878_ref1-bib97","doi-asserted-by":"publisher","first-page":"e1001886","DOI":"10.1371\/journal.pmed.1001886","article-title":"Individual participant data (IPD) meta-analyses of diagnostic and prognostic modeling studies: guidance on their use","volume":"12","author":"Debray","year":"2015","journal-title":"PLOS Med"},{"key":"key20181204135736878_ref1-bib98","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/aje\/kwt298","article-title":"Assessing risk prediction models using individual participant data from multiple studies","volume":"179","author":"Pennells","year":"2014","journal-title":"Am J Epidemiol"},{"key":"key20181204135736878_ref1-bib99","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jclinepi.2015.05.009","article-title":"Multivariate meta-analysis of individual participant data helped externally validate the performance and implementation of a prediction model","volume":"69","author":"Snell","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"key20181204135736878_ref1-bib100","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/art.21678","article-title":"Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial","volume":"54","author":"Smolen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib101","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/art.20123","article-title":"Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis","volume":"50","author":"Taylor","year":"2004","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib102","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/1529-0131(200201)46:1<21::AID-ART10061>3.0.CO;2-Q","article-title":"Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis","volume":"46","author":"Garnero","year":"2002","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib103","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1002\/acr.21978","article-title":"Association of high body mass index with decreased treatment response to combination therapy in recent-onset rheumatoid arthritis patients","volume":"65","author":"Heimans","year":"2013","journal-title":"Arthritis Care Res"},{"key":"key20181204135736878_ref1-bib104","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1136\/annrheumdis-2015-eular.1983","article-title":"Effect of anti-cyclic citrullinated peptide 2 immunoglobulin m serostatus on efficacy outcomes following treatment with abatacept plus methotrexate in the AVERT trial","volume":"74","author":"Huizinga","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib105","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1002\/acr.21758","article-title":"Serum cotinine as a biomarker of tobacco exposure and the association with treatment response in early rheumatoid arthritis","volume":"64","author":"Maska","year":"2012","journal-title":"Arthritis Care Res"},{"key":"key20181204135736878_ref1-bib106","first-page":"500","article-title":"Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies","volume":"29","author":"Mustila","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"key20181204135736878_ref1-bib107","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/art.1780390618","article-title":"Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A","volume":"39","author":"Pasero","year":"1996","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib108","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1093\/rheumatology\/37.11.1220","article-title":"Progression in early erosive rheumatoid arthritis: 12 month results from a randomized controlled trial comparing methotrexate and gold sodium thiomalate","volume":"37","author":"Rau","year":"1998","journal-title":"Br J Rheumatol"},{"key":"key20181204135736878_ref1-bib109","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1186\/ar4439","article-title":"ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial","volume":"16","author":"Seegobin","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"key20181204135736878_ref1-bib110","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1136\/annrheumdis-2015-207942","article-title":"Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial","volume":"75","author":"Sokolove","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib111","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1093\/rheumatology\/keh135","article-title":"How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to \u2018non-aggressive\u2019 DMARD treatment and perspective from a 2-yr open label trial","volume":"43","author":"Matteson","year":"2004","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib112","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","article-title":"A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis","volume":"343","author":"Bathon","year":"2000","journal-title":"N Engl J Med"},{"key":"key20181204135736878_ref1-bib113","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1136\/ard.2008.092254","article-title":"Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis","volume":"68","author":"van der Kooij","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib114","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1136\/ard.2007.076299","article-title":"Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis","volume":"67","author":"Choy","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib115","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/art.37711","article-title":"Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study","volume":"65","author":"Weinblatt","year":"2013","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib116","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2014-206106","article-title":"Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period","volume":"74","author":"Emery","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib117","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1002\/art.34498","article-title":"A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial","volume":"64","author":"Moreland","year":"2012","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib118","volume-title":"PROBAST: Prediction Model Risk of Bias Assessment Tool","author":"Moons","year":"2017"},{"key":"key20181204135736878_ref1-bib119","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/hir.12004","article-title":"Utilisation of search filters in systematic reviews of prognosis questions","volume":"29","author":"Chatterley","year":"2012","journal-title":"Health Info Libr J"},{"key":"key20181204135736878_ref1-bib120","doi-asserted-by":"publisher","first-page":"e32844","DOI":"10.1371\/journal.pone.0032844","article-title":"Search filters for finding prognostic and diagnostic prediction studies in Medline to enhance systematic reviews","volume":"7","author":"Geersing","year":"2012","journal-title":"PLOS ONE"},{"key":"key20181204135736878_ref1-bib121","first-page":"50","article-title":"Text mining and visualization using VOS Viewer","volume":"7","author":"van Eck","year":"2011","journal-title":"ISSI Newsletter"},{"key":"key20181204135736878_ref1-bib122","first-page":"139","article-title":"Prevalence of and predictive factors for sustained remission in early RA: results from SONORA study","volume":"7","author":"Akhavan","year":"2011","journal-title":"Reumatol Clin Suplementos"},{"key":"key20181204135736878_ref1-bib123","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1136\/annrheumdis-2014-eular.2233","article-title":"Development and validation of a prognostic clinical model for rapid radiographic progression in patients with RA","volume":"73","author":"Alemao","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib124","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1136\/annrheumdis-2012-201517","article-title":"Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity","volume":"72","author":"Aletaha","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib125","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s10165-008-0092-6","article-title":"Logistic regression models for predicting physical and mental health-related quality of life in rheumatoid arthritis patients","volume":"18","author":"Alishiri","year":"2008","journal-title":"Mod Rheumatol"},{"key":"key20181204135736878_ref1-bib126","unstructured":"Allaart CF, Dirven L, Hirata S, Kerstens PJSM, Dijkmans BAC, Chernoff D, et al. A Multi-Biomarker Disease Activity (Vectra DA) Algorithm Score for Rheumatoid Arthritis Predicts Radiographic Progression in the BeSt Study. American College of Rheumatology\/Association of Rheumatology Health Professionals (ACR\/ARHP) Annual Scientific Meeting, Chicago, IL, 4\u20139 November 2011."},{"key":"key20181204135736878_ref1-bib127","first-page":"1775","article-title":"The ACR\/EULAR 2010 criteria as well as other predictive algorithms for rheumatoid arthritis show good diagnostic performance","volume":"62","author":"Alves","year":"2010","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib128","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO;2-9","article-title":"Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration","volume":"43","author":"Anderson","year":"2000","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib129","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1093\/rheumatology\/kep380","article-title":"Prediction of functional impairment and remission in rheumatoid arthritis patients by biochemical variables and genetic polymorphisms","volume":"49","author":"Balsa","year":"2010","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib130","first-page":"1753","article-title":"Development of a multi-biomarker test for rheumatoid arthritis (RA) disease activity (Vectra DA)","volume":"62","author":"Bakker","year":"2010","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib131","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1136\/annrheumdis-2011-200963","article-title":"Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study","volume":"71","author":"Bakker","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib132","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/annrheumdis-2014-eular.2946","article-title":"Socio-demographic and health status characteristics explain clinical outcome trajectories in Early Inflammatory Arthritis (EIA)","volume":"73","author":"Barnabe","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib133","doi-asserted-by":"publisher","first-page":"548502","DOI":"10.1155\/2013\/548502","article-title":"Validation of a prediction rule for the diagnosis of rheumatoid arthritis in patients with recent onset undifferentiated arthritis","volume":"2013","author":"Bedran","year":"2013","journal-title":"Int J Rheumatol"},{"key":"key20181204135736878_ref1-bib134","first-page":"2534","article-title":"Risk factors for radiographic articular destruction of hands and wrists in rheumatoid arthritis","volume":"26","author":"Belghomari","year":"1999","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib135","unstructured":"Bombardier C. Which subgroups are at higher risk of rapid radiographic progression in early rheumatoid arthritis: results from SONORA study. Paper presented at the American College of Rheumatology conference. Philadelphia, Pennsylvania, 16\u201321 October 2009."},{"key":"key20181204135736878_ref1-bib136","first-page":"1321","article-title":"Radiographic damage and radiographic progression are predictors for physical function: results from SONORA study","volume":"37","author":"Bombardier","year":"2010","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib137","first-page":"336","article-title":"Sustained remission in early RA: results from SONORA study","volume":"62","author":"Bombardier","year":"2010","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib138","first-page":"1321","article-title":"Clinical prognostic factors for radiographic damage in early rheumatoid arthritis: results from SONORA study","volume":"37","author":"Bombardier","year":"2010","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib139","doi-asserted-by":"publisher","first-page":"R103","DOI":"10.1186\/ar2749","article-title":"Antibodies to cyclic citrullinated protein and erythrocyte sedimentation rate predict hand bone loss in patients with rheumatoid arthritis of short duration: a longitudinal study","volume":"11","author":"B\u00f8yesen","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"key20181204135736878_ref1-bib140","first-page":"22","article-title":"Multiple faces of rheumatoid arthritis: diagnostic and therapeutic algorithms","volume":"3","author":"Breedveld","year":"2004","journal-title":"Autoimmun Rev"},{"key":"key20181204135736878_ref1-bib141","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1136\/ard.2010.148619","article-title":"Validation of the 2010 ACR\/EULAR classification criteria for rheumatoid arthritis: slight improvement over the 1987 ACR criteria","volume":"70","author":"Britsemmer","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib142","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/art.22410","article-title":"Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis: a potential marker of erosive joint destruction","volume":"56","author":"Brown","year":"2007","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib143","first-page":"2306","article-title":"Detecting radiological changes in rheumatoid arthritis that are considered important by clinical experts: influence of reading with or without known sequence","volume":"29","author":"Bruynesteyn","year":"2002","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib144","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/art.10167","article-title":"Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort","volume":"46","author":"Bukhari","year":"2002","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib145","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13075-016-0935-z","article-title":"Serum levels of 14-3-3\u03b7 protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis","volume":"18","author":"Carrier","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"key20181204135736878_ref1-bib146","first-page":"1263","article-title":"Clinical, laboratory and radiographic features in early rheumatoid arthritis","volume":"17","author":"Caruso","year":"1990","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib147","doi-asserted-by":"publisher","first-page":"S697","DOI":"10.1371\/journal.pone.0079370","article-title":"Circulating CD4+CD161+ T lymphocytes are increased in seropositive arthralgia patients but decreased in patients with newly diagnosed rheumatoid arthritis","volume":"65","author":"Chalan","year":"2013","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib148","doi-asserted-by":"publisher","first-page":"e24380","DOI":"10.1371\/journal.pone.0024380","article-title":"Genetic risk score predicting risk of rheumatoid arthritis phenotypes and age of symptom onset","volume":"6","author":"Chibnik","year":"2011","journal-title":"PLOS ONE"},{"key":"key20181204135736878_ref1-bib149","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1007\/s10067-016-3326-6","article-title":"Ultrasound-detected subclinical inflammation was better reflected by the disease activity score (DAS-28) in patients with suspicion of inflammatory arthritis compared to established rheumatoid arthritis","volume":"35","author":"Ciurtin","year":"2016","journal-title":"Clin Rheumatol"},{"key":"key20181204135736878_ref1-bib150","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/rheumatology\/keq178","article-title":"Persistently moderate DAS-28 is not benign: loss of function occurs in early RA despite step-up DMARD therapy","volume":"49","author":"Conaghan","year":"2010","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib151","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10067-010-1639-4","article-title":"Predicting outcomes in rheumatoid arthritis","volume":"30","author":"Conaghan","year":"2011","journal-title":"Clin Rheumatol"},{"key":"key20181204135736878_ref1-bib152","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/rheumatology\/XXVII.suppl_2.171","article-title":"The Middlesex Hospital prospective study of early rheumatoid disease","volume":"27","author":"Corbett","year":"1988","journal-title":"Br J Rheumatol"},{"key":"key20181204135736878_ref1-bib153","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1093\/rheumatology\/32.8.717","article-title":"Factors predicting death, survival and functional outcome in a prospective study of early rheumatoid disease over fifteen years","volume":"32","author":"Corbett","year":"1993","journal-title":"Br J Rheumatol"},{"key":"key20181204135736878_ref1-bib154","doi-asserted-by":"publisher","first-page":"R106","DOI":"10.1186\/ar2498","article-title":"Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study","volume":"10","author":"Courvoisier","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"key20181204135736878_ref1-bib155","first-page":"1782","article-title":"Validation of a multi-biomarker test for rheumatoid arthritis (RA) disease activity (Vectra DA) in a multi-cohort study","volume":"62","author":"Curtis","year":"2010","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib156","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/acr.21767","article-title":"Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity","volume":"64","author":"Curtis","year":"2012","journal-title":"Arthritis Care Res"},{"key":"key20181204135736878_ref1-bib157","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1002\/art.39322","article-title":"A randomized trial comparing disease activity measures for the assessment and prediction of response in rheumatoid arthritis patients initiating certolizumab pegol","volume":"67","author":"Curtis","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib158","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1136\/ard.45.11.945","article-title":"Prediction of progressive joint damage in patients with rheumatoid arthritis receiving gold or D-penicillamine therapy","volume":"45","author":"Dawes","year":"1986","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib159","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1177\/028418518002100419","article-title":"Radiographic progression of rheumatoid arthritis related to some clinical and laboratory parameters","volume":"21","author":"de Carvalho","year":"1980","journal-title":"Acta Radiol Diagn"},{"key":"key20181204135736878_ref1-bib160","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3899\/jrheum.140085","article-title":"Personalizing treatment targets in rheumatoid arthritis by using a simple prediction model","volume":"42","author":"de Punder","year":"2015","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib161","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1002\/art.23439","article-title":"Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies","volume":"58","author":"de Vries-Bouwstra","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib162","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13075-015-0599-0","article-title":"An external validation study reporting poor correlation between the claims-based index for rheumatoid arthritis severity and the disease activity score","volume":"17","author":"Desai","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"key20181204135736878_ref1-bib163","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jpba.2012.06.003","article-title":"Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis","volume":"70","author":"Eastman","year":"2012","journal-title":"J Pharm Biomed Anal"},{"key":"key20181204135736878_ref1-bib164","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/BF02274837","article-title":"Early rheumatoid arthritis \u2013 onset, course, and outcome over 2 years","volume":"10","author":"Eberhardt","year":"1990","journal-title":"Rheumatol Int"},{"key":"key20181204135736878_ref1-bib165","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1136\/ard.55.1.34","article-title":"Associations of HLA-DRB and -DQB genes with two and five year outcome in rheumatoid arthritis","volume":"55","author":"Eberhardt","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib166","doi-asserted-by":"publisher","first-page":"A77","DOI":"10.1136\/annrheumdis-2013-203224.15","article-title":"IgA rheumatoid factor is more predominant than anti-CCP in Sudanese rheumatoid arthritis patients, whereas IgG RF is a strong prognostic marker and associate D with early onset","volume":"72","author":"Elshafie","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib167","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1136\/bmj.313.7069.1398","article-title":"Algorithm to predict radiological erosions in early rheumatoid arthritis. Messages from paper are incorrect","volume":"313","author":"Emery","year":"1996","journal-title":"BMJ"},{"key":"key20181204135736878_ref1-bib168","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1093\/rheumatology\/kem257","article-title":"Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis","volume":"47","author":"Emery","year":"2008","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib169","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1136\/ard.2006.056937","article-title":"Sex: a major predictor of remission in early rheumatoid arthritis?","volume":"66","author":"Forslind","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib170","doi-asserted-by":"crossref","unstructured":"Fautrel B, Granger B, Combe BG, Le Loet XX. Identification of Patients Who Could Require Early Biologic Therapy by Developing a Matrix Predicting Rapid Radiographic Progression in Early Rheumatoid Arthritis Patients Treated by Methotrexate. A Study Based on the ESPOIR Cohort Data. American College of Rheumatology\/Association of Rheumatology Health Professionals (ACR\/ARHP) Annual Scientific Meeting, Chicago, IL, 4\u20139 November 2011.","DOI":"10.1186\/ar4092"},{"key":"key20181204135736878_ref1-bib171","first-page":"S786","article-title":"Value of matrices developed to identify early rheumatoid arthritis patients with rapid radiographic progression despite methotrexate therapy: a comparison of their performance in the early rheumatoid arthritis ESPOIR cohort","volume":"64","author":"Fautrel","year":"2012","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib172","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/annrheumdis-2012-eular.2526","article-title":"Performance of rapid radiographic progression prediction matrices in the early rheumatoid arthritis patients of the ESPOIR cohort","volume":"71","author":"Fautrel","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib173","doi-asserted-by":"publisher","first-page":"e000018","DOI":"10.1136\/rmdopen-2014-000018","article-title":"Identifying patients with rheumatoid arthritis with moderate disease activity at risk of significant radiographic progression despite methotrexate treatment","volume":"1","author":"Fautrel","year":"2015","journal-title":"RMD Open"},{"key":"key20181204135736878_ref1-bib174","first-page":"1785","article-title":"Validity of the revised ACR\/EULAR classification criteria for rheumatoid arthritis: predicting persistent arthritis and joint erosions after 2 years in patients with early undifferentiated arthritis","volume":"62","author":"Fransen","year":"2010","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib175","unstructured":"Gardiner J, Su B, Ellis B, Soljak M. Estimating Under-Diagnosis of Rheumatoid Arthritis in Primary Care Data from the UK Clinical Practice Research Datalink. American College of Rheumatology\/Association of Rheumatology Health Professionals (ACR\/ARHP) Annual Scientific Meeting, San Francisco, CA, 6\u201311 November 2015."},{"key":"key20181204135736878_ref1-bib176","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/art.11445","article-title":"Prognostic markers of radiographic progression in early rheumatoid arthritis","volume":"50","author":"Goronzy","year":"2004","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib177","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/03009740310004847","article-title":"The natural history and prognosis of rheumatoid arthritis: association of radiographic outcome with process variables, joint motion and immune proteins","volume":"118","author":"Graudal","year":"2004","journal-title":"Scand J Rheumatol Suppl"},{"key":"key20181204135736878_ref1-bib178","first-page":"i","article-title":"Scandinavian Journal of Rheumatology: preface","volume":"33","author":"Graudal","year":"2004","journal-title":"Scand J Rheumatol"},{"key":"key20181204135736878_ref1-bib179","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/rheumatology\/keg037","article-title":"Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis","volume":"42","author":"Green","year":"2003","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib180","first-page":"S174","article-title":"Can sustained remission of rheumatoid arthritis be predicted? An analysis from the Japanese national database of rheumatic disease (NinJa)","volume":"64","author":"Haji","year":"2012","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib181","doi-asserted-by":"publisher","first-page":"A593","DOI":"10.1136\/annrheumdis-2013-eular.1765","article-title":"A prediction rule for sustained remission of rheumatoid arthritis","volume":"72","author":"Haji","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib182","doi-asserted-by":"publisher","first-page":"A388","DOI":"10.1136\/annrheumdis-2013-eular.1187","article-title":"A multi-biomarker disease activity blood test (Vectra DA) correlates with radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial","volume":"72","author":"Hambardzumyan","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib183","first-page":"S555","article-title":"A multi-biomarker disease activity score correlates with radiographic progression in early rheumatoid arthritis: results from a randomized trial","volume":"65","author":"Hambardzumyan","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib184","doi-asserted-by":"publisher","first-page":"A388","DOI":"10.1136\/annrheumdis-2013-eular.1188","article-title":"Multi-biomarker disease activity (MBDA) score and the 12 individual biomarkers in early rheumatoid arthritis patients relate differentially to clinical response and radiographic progression: results from the SWEFOT trial","volume":"72","author":"Hambardzumyan","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib185","first-page":"S762","article-title":"In early rheumatoid arthritis, the 12 individual biomarkers that comprise the multiple biomarker disease activity score relate differentially to clinical response and radiographic progression: results from a randomized trial","volume":"65","author":"Hambardzumyan","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib186","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1002\/1529-0131(199910)42:10<2174::AID-ANR19>3.0.CO;2-G","article-title":"The influence of HLA-DRB1 alleles and rheumatoid factor on disease outcome in an inception cohort of patients with early inflammatory arthritis","volume":"42","author":"Harrison","year":"1999","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib187","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/1529-0131(200102)44:2<323::AID-ANR49>3.0.CO;2-C","article-title":"The association of cigarette smoking with disease outcome in patients with early inflammatory polyarthritis","volume":"44","author":"Harrison","year":"2001","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib188","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nrrheum.2011.78","article-title":"The epidemiology of early inflammatory arthritis","volume":"7","author":"Hazes","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"key20181204135736878_ref1-bib189","first-page":"S1135","article-title":"Moving towards personalized healthcare: a patient reported outcome based algorithm can aid rheumatologists and patients in monitoring rheumatoid arthritis in daily clinical practice","volume":"65","author":"Hendrikx","year":"2013","journal-title":"RMD Open"},{"key":"key20181204135736878_ref1-bib190","doi-asserted-by":"publisher","first-page":"e000114","DOI":"10.1136\/rmdopen-2015-000114","article-title":"Monitoring rheumatoid arthritis using an algorithm based on patient-reported outcome measures: a first step towards personalised healthcare","volume":"1","author":"Hendrikx","year":"2015","journal-title":"RMD Open"},{"key":"key20181204135736878_ref1-bib191","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1093\/rheumatology\/kes362","article-title":"A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study","volume":"52","author":"Hirata","year":"2013","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib192","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2177\/jsci.39.37","article-title":"Assessment of disease activity in rheumatoid arthritis by multi-biomarker disease activity (MBDA) score","volume":"39","author":"Hirata","year":"2016","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"key":"key20181204135736878_ref1-bib193","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1080\/030097498441173","article-title":"Rheumatoid factor isotypes, disease activity and the outcome of rheumatoid arthritis: comparative effects of different antigens","volume":"27","author":"Houssien","year":"1998","journal-title":"Scand J Rheumatol"},{"key":"key20181204135736878_ref1-bib194","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/rheumatology\/keh059","article-title":"Orthopaedic intervention in early rheumatoid arthritis. Occurrence and predictive factors in an inception cohort of 1064 patients followed for 5 years","volume":"43","author":"James","year":"2004","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib195","first-page":"S515","article-title":"Assessing the validity and reliability of a novel MRI semi-automated algorithm for quantifying bone loss in the hand","volume":"66","author":"Jessome","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib196","first-page":"1320","article-title":"Early erosions in rheumatoid arthritis (EERA) software reliably measures erosive damage on MRI in the metacarpophalangeal joints of rheumatoid arthritis patients","volume":"42","author":"Jessome","year":"2015","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib197","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/03009748509104317","article-title":"Prognostic factors and diagnostic criteria in early rheumatoid arthritis","volume":"57","author":"Kaarela","year":"1985","journal-title":"Scand J Rheumatol Suppl"},{"key":"key20181204135736878_ref1-bib198","doi-asserted-by":"publisher","first-page":"A817","DOI":"10.1136\/annrheumdis-2013-eular.2428","article-title":"The impact of inflammation on metabolomic profiles in patients with arthritis","volume":"72","author":"Kapoor","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib199","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1136\/annrheumdis-2014-205698","article-title":"Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial","volume":"75","author":"Kastbom","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib200","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1136\/annrheumdis-2012-eular.294","article-title":"Comparison between several prediction scores and the new EULAR\/ACR criteria for diagnosis and prognosis of rheumatoid arthritis","volume":"71","author":"Kaufmann","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib201","doi-asserted-by":"publisher","first-page":"M51","DOI":"10.1097\/00005650-199905001-00005","article-title":"The SF-36 Arthritis-Specific Health Index (ASHI): II. Tests of validity in four clinical trials","volume":"37","author":"Keller","year":"1999","journal-title":"Med Care"},{"key":"key20181204135736878_ref1-bib202","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/gepi.20470","article-title":"Analysis of multiple phenotypes","volume":"33","author":"Kent","year":"2009","journal-title":"Genet Epidemiol"},{"key":"key20181204135736878_ref1-bib203","doi-asserted-by":"publisher","first-page":"842","DOI":"10.3109\/14397595.2015.1026025","article-title":"Predicting joint destruction in rheumatoid arthritis with power Doppler, anti-citrullinated peptide antibody, and joint swelling","volume":"25","author":"Kirino","year":"2015","journal-title":"Mod Rheumatol"},{"key":"key20181204135736878_ref1-bib204","first-page":"1371","article-title":"MRI-proven bone edema of wrist and finger joints at entry is the strongest predictor toward further radiographic progression in patients with undifferentiated arthritis: results from the prospective cohort at Nagasaki University","volume":"62","author":"Kita","year":"2010","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib205","first-page":"1277","article-title":"Biomarkers of inflammation in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity and radiographic outcome","volume":"35","author":"Knudsen","year":"2008","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib206","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1111\/1756-185X.12789","article-title":"Patient-reported outcomes as assessment tools and predictors of long-term prognosis: a 7-year follow-up study of patients with rheumatoid arthritis","volume":"20","author":"Kojima","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"key20181204135736878_ref1-bib207","doi-asserted-by":"publisher","first-page":"R50","DOI":"10.1186\/ar3293","article-title":"The role of synovial fluid markers of catabolism and anabolism in osteoarthritis, rheumatoid arthritis and asymptomatic organ donors","volume":"13","author":"Kokebie","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"key20181204135736878_ref1-bib208","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1093\/rheumatology\/ket011","article-title":"Risk of rheumatoid arthritis development in patients with unclassified arthritis according to the 2010 ACR\/EULAR criteria for rheumatoid arthritis","volume":"52","author":"Krabben","year":"2013","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib209","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1002\/1529-0131(200008)43:8<1831::AID-ANR19>3.0.CO;2-6","article-title":"The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis","volume":"43","author":"Kroot","year":"2000","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib210","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1136\/ard.59.10.805","article-title":"Data driven attempt to create a clinical algorithm for identification of women with rheumatoid arthritis at high risk of osteoporosis","volume":"59","author":"Kvien","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib211","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/annrheumdis-2012-202481","article-title":"Using lifestyle factors to identify individuals at higher risk of inflammatory polyarthritis (results from the European Prospective Investigation of Cancer-Norfolk and the Norfolk Arthritis Register \u2013 the EPIC-2-NOAR Study)","volume":"73","author":"Lahiri","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"key20181204135736878_ref1-bib212","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/annrheumdis-2012-eular.1729","article-title":"A risk score to identify individuals at higher risk of inflammatory polyarthritis: results from the European prospective investigation of cancer (Norfolk) and the Norfolk arthritis register (the EPIC-2-NOAR study)","volume":"73","author":"Lahiri","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib213","first-page":"8","article-title":"Predictive markers in rapidly progressing rheumatoid arthritis","volume":"80","author":"Landew\u00e9","year":"2007","journal-title":"J Rheumatol Suppl"},{"key":"key20181204135736878_ref1-bib214","first-page":"S759","article-title":"An algorithm including the intrasynovial expression of CD20 and serum biomarkers (rheumatoid factors, Anti-CCP2 and RANK-ligand) able to predict the progression of bone erosions in very early arthritis","volume":"58","author":"Lanfant","year":"2008","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib215","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jbspin.2011.11.006","article-title":"Synovium CD20 expression is a potential new predictor of bone erosion progression in very-early arthritis treated by sequential DMARDs monotherapy \u2013 a pilot study from the VErA cohort","volume":"79","author":"Lanfant-Weybel","year":"2012","journal-title":"Joint Bone Spine"},{"key":"key20181204135736878_ref1-bib216","doi-asserted-by":"publisher","first-page":"e0122104","DOI":"10.1371\/journal.pone.0122104","article-title":"Heterogeneity of synovial molecular patterns in patients with arthritis","volume":"10","author":"Lauwerys","year":"2015","journal-title":"PLOS ONE"},{"key":"key20181204135736878_ref1-bib217","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/acr.20321","article-title":"Serum IgA rheumatoid factor and pyridinoline in very early arthritis as predictors of erosion(s) at two years: a simple model of prediction from a conservatively treated community-based inception cohort","volume":"62","author":"Le Lo\u00ebt","year":"2010","journal-title":"Arthritis Care Res"},{"key":"key20181204135736878_ref1-bib218","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/rheumatology\/kev341","article-title":"Relationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis","volume":"55","author":"Li","year":"2016","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib219","doi-asserted-by":"publisher","first-page":"A403","DOI":"10.1136\/annrheumdis-2013-eular.1225","article-title":"Biomarker-based estimates of risk of radiographic progression in the Leiden early arthritis cohort","volume":"72","author":"Li","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib220","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1185\/03007995.2012.753042","article-title":"Impact of a multi-biomarker disease activity test on rheumatoid arthritis treatment decisions and therapy use","volume":"29","author":"Li","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"key20181204135736878_ref1-bib221","first-page":"372","article-title":"Clinical factors that predict erosion-free status in rheumatoid arthritis","volume":"60","author":"Liao","year":"2009","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib222","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1093\/rheumatology\/ker129","article-title":"Clinical predictors of erosion-free status in rheumatoid arthritis: a prospective cohort study","volume":"50","author":"Liao","year":"2011","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib223","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1136\/annrheumdis-2012-eular.2902","article-title":"The performance of matrix-based risk models for rapid radiographic progression in an observational cohort of established rheumatoid arthritis patients","volume":"71","author":"Lillegraven","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib224","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1136\/ard.61.12.1055","article-title":"Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage","volume":"61","author":"Lindqvist","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib225","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/ard.2003.019992","article-title":"Prognostic laboratory markers of joint damage in rheumatoid arthritis","volume":"64","author":"Lindqvist","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib226","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1136\/ard.2006.066704","article-title":"Arthritis of the large joints - in particular, the knee \u2013 at first presentation is predictive for a high level of radiological destruction of the small joints in rheumatoid arthritis","volume":"66","author":"Linn-Rasker","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib227","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1136\/annrheumdis-2014-eular.2151","article-title":"Factors associated with major depressive disorder in rheumatoid arthritis patients","volume":"73","author":"Lisitsyna","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib228","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1136\/annrheumdis-2015-eular.2488","article-title":"Depression as a risk factor for joints destruction in rheumatoid arthritis patients","volume":"74","author":"Lisitsyna","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib229","doi-asserted-by":"publisher","first-page":"484351","DOI":"10.4061\/2009\/484351","article-title":"Prediction of disease severity in patients with early rheumatoid arthritis by gene expression profiling","volume":"2009","author":"Liu","year":"2009","journal-title":"Hum Genomics Proteomics"},{"key":"key20181204135736878_ref1-bib230","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s00296-015-3274-5","article-title":"Physical activity and the association with fatigue and sleep in Danish patients with rheumatoid arthritis","volume":"35","author":"L\u00f8ppenthin","year":"2015","journal-title":"Rheumatol Int"},{"key":"key20181204135736878_ref1-bib231","first-page":"295","article-title":"The prediction of radiological destruction during the early stage of rheumatoid arthritis","volume":"1","author":"Luukkainen","year":"1983","journal-title":"Clin Exp Rheumatol"},{"key":"key20181204135736878_ref1-bib232","first-page":"S1300","article-title":"Multi-biomarker disease activity score is associated with power Doppler ultrasound in patients with rheumatoid arthritis in low disease activity state","volume":"66","author":"Ma","year":"2014","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib233","first-page":"iii75","article-title":"Biomarker signature in rheumatoid arthritis patients with low disease activity: the REMIRA study","volume":"51","author":"Ma","year":"2012","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib234","article-title":"Investigation of a multi-biomarker disease activity (Vectra DA) signature and algorithm score in rheumatoid arthritis patients with low disease activity: the REMIRA study","volume":"63","author":"Ma","year":"2011","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib235","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.3899\/jrheum.131401","article-title":"Clinical and serological predictors of remission in rheumatoid arthritis are dependent on treatment regimen","volume":"41","author":"Ma","year":"2014","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib236","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3899\/jrheum.110169","article-title":"Remission in early rheumatoid arthritis: predicting treatment response","volume":"39","author":"Ma","year":"2012","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib237","first-page":"2278","article-title":"Very recent onset arthritis \u2013 clinical, laboratory, and radiological findings during the first year of disease","volume":"29","author":"Machold","year":"2002","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib238","first-page":"E98","article-title":"Serum matrix metalloproteinase-3 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological disease modifying anti-rheumatic drugs","volume":"56","author":"Mamehara","year":"2010","journal-title":"Kobe J Med Sci"},{"key":"key20181204135736878_ref1-bib239","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/art.23188","article-title":"Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides","volume":"58","author":"Mathsson","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib240","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1753-6561-1-s1-s17","article-title":"Evaluating gene\u2009\u00d7\u2009gene and gene\u2009\u00d7\u2009smoking interaction in rheumatoid arthritis using candidate genes in GAW15","volume":"1","author":"Mei","year":"2007","journal-title":"BMC Proc"},{"key":"key20181204135736878_ref1-bib241","first-page":"S964","article-title":"The diagnostic accuracy of rheumatoid factor testing in primary Care","volume":"65","author":"Miller","year":"2013","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib242","doi-asserted-by":"publisher","first-page":"i29","DOI":"10.1093\/rheumatology\/keu086.002","article-title":"Negative rheumatoid factor in primary care delays referral of patients with rheumatoid arthritis","volume":"53","author":"Miller","year":"2014","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib243","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1515\/CCLM.2006.026","article-title":"Diagnosis and prognosis of early rheumatoid arthritis, with special emphasis on laboratory analysis","volume":"44","author":"Mierau","year":"2006","journal-title":"Clin Chem Lab Med"},{"key":"key20181204135736878_ref1-bib244","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/annrheumdis-2012-202709","article-title":"Anaemia may add information to standardised disease activity assessment to predict radiographic damage in rheumatoid arthritis: a prospective cohort study","volume":"73","author":"M\u00f6ller","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib245","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.berh.2004.08.008","article-title":"How to predict prognosis in early rheumatoid arthritis","volume":"19","author":"Morel","year":"2005","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"key20181204135736878_ref1-bib246","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1136\/ard.47.8.648","article-title":"Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis","volume":"47","author":"M\u00f6tt\u00f6nen","year":"1988","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib247","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1136\/ard.57.9.533","article-title":"Only high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with \u2018sawtooth\u2019 strategy","volume":"57","author":"M\u00f6tt\u00f6nen","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib248","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.3899\/jrheum.150988","article-title":"Magnetic resonance imaging bone edema at enrollment predicts rapid radiographic progression in patients with early RA: results from the Nagasaki University early arthritis cohort","volume":"43","author":"Nakashima","year":"2016","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib249","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1136\/ard.2005.035691","article-title":"Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis","volume":"64","author":"Nell","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib250","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1136\/ard.2004.029389","article-title":"Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis","volume":"64","author":"Nielen","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib251","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1089\/tmj.2013.0162","article-title":"Self-assessment tool of disease activity of rheumatoid arthritis by using a smartphone application","volume":"20","author":"Nishiguchi","year":"2014","journal-title":"Telemed J E Health"},{"key":"key20181204135736878_ref1-bib252","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3414\/ME14-01-0106","article-title":"Self-assessment of rheumatoid arthritis disease activity using a smartphone application. Development and 3-month feasibility study","volume":"55","author":"Nishiguchi","year":"2016","journal-title":"Methods Inf Med"},{"key":"key20181204135736878_ref1-bib253","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1093\/rheumatology\/ket253","article-title":"Trajectories of functional limitation in early rheumatoid arthritis and their association with mortality","volume":"52","author":"Norton","year":"2013","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib254","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/rheumatology\/kes262","article-title":"A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in RA and their impact on outcome","volume":"52","author":"Norton","year":"2013","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib255","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.semarthrit.2014.05.003","article-title":"Health Assessment Questionnaire disability progression in early rheumatoid arthritis: systematic review and analysis of two inception cohorts","volume":"44","author":"Norton","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib256","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/art.21548","article-title":"Association of early radiographic damage with impaired physical function in rheumatoid arthritis: a ten-year, longitudinal observational study in 238 patients","volume":"54","author":"\u00d8deg\u00e5rd","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib257","first-page":"861","article-title":"Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients?","volume":"23","author":"Papadopoulos","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"key20181204135736878_ref1-bib258","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.cct.2010.11.009","article-title":"Patterns of radiographic outcomes in early, seropositive rheumatoid arthritis: a baseline analysis","volume":"32","author":"Park","year":"2011","journal-title":"Contemp Clin Trials"},{"key":"key20181204135736878_ref1-bib259","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00296-013-2879-9","article-title":"Examining radiographic outcomes over time","volume":"34","author":"Park","year":"2014","journal-title":"Rheumatol Int"},{"key":"key20181204135736878_ref1-bib260","first-page":"1808","article-title":"Measurement and prediction of radiological progression in early rheumatoid arthritis","volume":"21","author":"Plant","year":"1994","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib261","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1002\/1529-0131(200007)43:7<1473::AID-ANR9>3.0.CO;2-N","article-title":"Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis","volume":"43","author":"Plant","year":"2000","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib262","first-page":"2761","article-title":"Serum matrix metalloproteinase 3 in early rheumatoid arthritis is correlated with disease activity and radiological progression","volume":"27","author":"Posthumus","year":"2000","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib263","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1093\/rheumatology\/kew048","article-title":"Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (Norway): results from Norwegian cohort study NOR-DMARD","volume":"55","author":"Putrik","year":"2016","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib264","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1002\/art.11269","article-title":"Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol","volume":"48","author":"Quinn","year":"2003","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib265","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/rheumatology\/kei203","article-title":"Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome","volume":"45","author":"Quinn","year":"2006","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib266","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1136\/annrheumdis-2015-207900","article-title":"Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment","volume":"75","author":"Rech","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib267","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1136\/annrheumdis-2011-200038","article-title":"In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial","volume":"71","author":"Rezaei","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib268","doi-asserted-by":"publisher","first-page":"e1000341","DOI":"10.1371\/journal.pmed.1000341","article-title":"A genetic association study of serum acute-phase C-reactive protein levels in rheumatoid arthritis: implications for clinical interpretation","volume":"7","author":"Rhodes","year":"2010","journal-title":"PLOS Med"},{"key":"key20181204135736878_ref1-bib269","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1136\/ard.2010.139212","article-title":"Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial","volume":"70","author":"Saevarsdottir","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib270","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/art.27758","article-title":"Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts","volume":"63","author":"Saevarsdottir","year":"2011","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib271","first-page":"365","article-title":"A predictive algorithm combining routine assessment and power Doppler ultrasonography for the development of rheumatoid arthritis from an early-onset undifferentiated arthritis","volume":"60","author":"Salaffi","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib272","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1136\/ard.2010.146506","article-title":"Distinct ACPA fine specificities, formed under the influence of HLA shared epitope alleles, have no effect on radiographic joint damage in rheumatoid arthritis","volume":"70","author":"Scherer","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib273","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/oxfordjournals.rheumatology.a031490","article-title":"Prognostic factors in early rheumatoid arthritis","volume":"39","author":"Scott","year":"2000","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib274","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.1016\/S0140-6736(13)60537-1","article-title":"Prediction model for rheumatoid arthritis: modelling 46 genetic risk variants with smoking","volume":"381","author":"Scott","year":"2013","journal-title":"Lancet"},{"key":"key20181204135736878_ref1-bib275","doi-asserted-by":"crossref","DOI":"10.1161\/circ.130.suppl_2.13659","article-title":"Development of a transatlantic cardiovascular risk calculator for rheumatoid arthritis (ATACC-RA)","volume":"130","author":"Semb","year":"2014","journal-title":"Circulation"},{"key":"key20181204135736878_ref1-bib276","first-page":"S5","article-title":"Development of a transatlantic cardiovascular risk calculator for rheumatoid arthritis","volume":"22","author":"Semb","year":"2015","journal-title":"Eur J Prev Cardiol"},{"key":"key20181204135736878_ref1-bib277","first-page":"1496","article-title":"Serum biomarkers predict progressive structural damage in the BeSt study","volume":"62","author":"Shen","year":"2010","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib278","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/biom.12223","article-title":"Sparse kernel machine regression for ordinal outcomes","volume":"71","author":"Shen","year":"2015","journal-title":"Biometrics"},{"key":"key20181204135736878_ref1-bib279","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3109\/03009748409102663","article-title":"Factors related to the progression of joint destruction in rheumatoid arthritis","volume":"13","author":"Sj\u00f6blom","year":"1984","journal-title":"Scand J Rheumatol"},{"key":"key20181204135736878_ref1-bib280","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2012-202361","article-title":"Forget personalised medicine and focus on abating disease activity","volume":"72","author":"Smolen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib281","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1002\/art.39195","article-title":"Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: a Consortium of Rheumatology Researchers of North America Registry Study","volume":"67","author":"Solomon","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib282","first-page":"S1131","article-title":"Performance of prediction models for rheumatoid arthritis serologic phenotypes among women using family history, genetics and environmental factors","volume":"65","author":"Sparks","year":"2013","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib283","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/00002281-199705000-00009","article-title":"Management of rheumatoid arthritis","volume":"9","author":"Stucki","year":"1997","journal-title":"Curr Opin Rheumatol"},{"key":"key20181204135736878_ref1-bib284","first-page":"1438","article-title":"Outcome in rheumatoid arthritis. A 1985 inception cohort study","volume":"21","author":"Suarez-Almazor","year":"1994","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib285","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1136\/ard.2009.113092","article-title":"Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study","volume":"69","author":"Syversen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib286","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1136\/ard.62.11.1094","article-title":"Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis","volume":"62","author":"Tchetverikov","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib287","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/ard.43.5.673","article-title":"Prospective study of early rheumatoid arthritis. I. Prognostic value of IgA rheumatoid factor","volume":"43","author":"Teitsson","year":"1984","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib288","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1186\/ar2482","article-title":"Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study","volume":"10","author":"Ting","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"key20181204135736878_ref1-bib289","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1002\/acr.22078","article-title":"First-year radiographic progression as a predictor of further progression in early arthritis: results of a large national French cohort","volume":"65","author":"Tob\u00f3n","year":"2013","journal-title":"Arthritis Care Res"},{"key":"key20181204135736878_ref1-bib290","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/rheumatology\/39.7.732","article-title":"The course of rheumatoid arthritis and predictors of psychological, physical and radiographic outcome after 5 years of follow-up","volume":"39","author":"Uhlig","year":"2000","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib291","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.berh.2015.09.001","article-title":"How does established rheumatoid arthritis develop, and are there possibilities for prevention?","volume":"29","author":"van Beers-Tas","year":"2015","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"key20181204135736878_ref1-bib292","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/annrheumdis-2012-eular.2516","article-title":"The clinical relevance of rapid radiological progression in the first year of treatment during 8 years of follow-up of early rheumatoid arthritis patients","volume":"71","author":"van Den Broek","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib293","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1136\/annrheumdis-2011-201212","article-title":"Rapid radiological progression in the first year of early rheumatoid arthritis is predictive of disability and joint damage progression during 8 years of follow-up","volume":"71","author":"van den Broek","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib294","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/rheumatology\/31.8.519","article-title":"Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients","volume":"31","author":"van der Heijde","year":"1992","journal-title":"Br J Rheumatol"},{"key":"key20181204135736878_ref1-bib295","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/art.1780381013","article-title":"Prediction of progression of radiologic damage in newly diagnosed rheumatoid arthritis","volume":"38","author":"van der Heide","year":"1995","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib296","doi-asserted-by":"publisher","first-page":"R949","DOI":"10.1186\/ar1767","article-title":"Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis","volume":"7","author":"van der Helm-van Mil","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"key20181204135736878_ref1-bib297","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1002\/art.23681","article-title":"Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making","volume":"58","author":"van der Helm-van Mil","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib298","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1136\/ard.2009.123828","article-title":"Genetic variants in the prediction of rheumatoid arthritis","volume":"69","author":"van der Helm-van Mil","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib299","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1093\/rheumatology\/kes378","article-title":"An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression","volume":"52","author":"van der Helm-van Mil","year":"2013","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib300","first-page":"689","article-title":"The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis","volume":"17","author":"van Jaarsveld","year":"1999","journal-title":"Clin Exp Rheumatol"},{"key":"key20181204135736878_ref1-bib301","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/annrheumdis-2013-204659","article-title":"Evaluating processes underlying the predictive value of baseline erosions for future radiological damage in early rheumatoid arthritis","volume":"74","author":"van Nies","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib302","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1136\/annrheumdis-2013-203718","article-title":"Anaemia to predict radiographic progression in rheumatoid arthritis","volume":"72","author":"van Steenbergen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib303","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/art.1780340707","article-title":"Association of HLA-DR4 with a more progressive disease course in patients with rheumatoid arthritis. Results of a followup study","volume":"34","author":"van Zeben","year":"1991","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib304","first-page":"1288","article-title":"Factors predicting outcome of rheumatoid arthritis: results of a followup study","volume":"20","author":"van Zeben","year":"1993","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib305","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.3899\/jrheum.101227","article-title":"Diagnostic accuracy of ACR\/EULAR 2010 criteria for rheumatoid arthritis in a 2-year cohort","volume":"38","author":"Varache","year":"2011","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib306","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/1477-7525-8-141","article-title":"Mapping onto Eq-5 D for patients in poor health","volume":"8","author":"Versteegh","year":"2010","journal-title":"Health Qual Life Outcomes"},{"key":"key20181204135736878_ref1-bib307","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1002\/acr.22057","article-title":"Association of tobacco exposure and reduction of radiographic progression in early rheumatoid arthritis: results from a French multicenter cohort","volume":"65","author":"Vesperini","year":"2013","journal-title":"Arthritis Care Res"},{"key":"key20181204135736878_ref1-bib308","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/art.10117","article-title":"How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis","volume":"46","author":"Visser","year":"2002","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib309","first-page":"1247","article-title":"The BeSt matrix model in recent-onset rheumatoid arthritis patients: individual prediction of rapid radiographic progression and numbers-needed-to-treat with initial combination therapy","volume":"60","author":"Visser","year":"2009","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib310","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1002\/art.24623","article-title":"The clinical relevance of a prediction rule for disease outcome in patients with undifferentiated arthritis: comment on the article by van der Helm-van Mil et al.","volume":"60","author":"Visser","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib311","first-page":"1465","article-title":"Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis","volume":"34","author":"Visvanathan","year":"2007","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib312","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1002\/art.22640","article-title":"A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis","volume":"56","author":"Wessels","year":"2007","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib313","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1136\/ard.45.10.809","article-title":"Serum immune complexes containing IgA appear to predict erosive arthritis in a longitudinal study in rheumatoid arthritis","volume":"45","author":"Westedt","year":"1986","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib314","doi-asserted-by":"publisher","first-page":"801","DOI":"10.7326\/0003-4819-117-10-801","article-title":"The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis","volume":"117","author":"Weyand","year":"1992","journal-title":"Ann Intern Med"},{"key":"key20181204135736878_ref1-bib315","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1002\/acr.22031","article-title":"Accuracy of Canadian health administrative databases in identifying patients with rheumatoid arthritis: a validation study using the medical records of rheumatologists","volume":"65","author":"Widdifield","year":"2013","journal-title":"Arthritis Care Res"},{"key":"key20181204135736878_ref1-bib316","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1002\/1529-0131(199809)41:9<1571::AID-ART7>3.0.CO;2-R","article-title":"Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression","volume":"41","author":"Wolfe","year":"1998","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib317","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1002\/1529-0131(200012)43:12<2751::AID-ANR15>3.0.CO;2-6","article-title":"A reappraisal of HAQ disability in rheumatoid arthritis","volume":"43","author":"Wolfe","year":"2000","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib318","first-page":"630","article-title":"The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis","volume":"27","author":"Wolfe","year":"2000","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib319","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.semarthrit.2003.12.002","article-title":"Development and evaluation of a patient self-report case-finding method for rheumatoid arthritis","volume":"34","author":"Wong","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib320","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1002\/1529-0131(200004)43:4<852::AID-ANR16>3.0.CO;2-7","article-title":"Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis","volume":"43","author":"Yamanaka","year":"2000","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib321","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/BF02203380","article-title":"A prospective study of early onset rheumatoid arthritis over fifteen years: prognostic features and outcome","volume":"6","author":"Young","year":"1987","journal-title":"Clin Rheumatol"},{"key":"key20181204135736878_ref1-bib322","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/rheumatology\/27.2.94","article-title":"A prognostic index for erosive changes in the hands, feet, and cervical spines in early rheumatoid arthritis","volume":"27","author":"Young","year":"1988","journal-title":"Br J Rheumatol"},{"key":"key20181204135736878_ref1-bib323","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0950-3579(97)80031-3","article-title":"Can we predict aggressive disease?","volume":"11","author":"Young","year":"1997","journal-title":"Baillieres Clin Rheumatol"},{"key":"key20181204135736878_ref1-bib324","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1136\/ard.59.10.794","article-title":"Socioeconomic deprivation and rheumatoid disease: what lessons for the health service?","volume":"59","author":"Young","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib325","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1002\/art.22923","article-title":"Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers","volume":"56","author":"Young-Min","year":"2007","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib326","first-page":"460","article-title":"Efficacy and safety of tocilizumab in refractory rheumatoid arthritis: a real life cohort from a single centre","volume":"32","author":"Addimanda","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"key20181204135736878_ref1-bib327","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1136\/annrheumdis-2012-eular.3028","article-title":"Clinical predictors of response to methotrexate treatment in DMARD naive patients with early rheumatoid arthritis: results from a longitudinal observational study","volume":"71","author":"Aga","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib328","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/acr.21710","article-title":"Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term followup from disease onset","volume":"65","author":"Ajeganova","year":"2013","journal-title":"Arthritis Care Res"},{"key":"key20181204135736878_ref1-bib329","first-page":"S935","article-title":"Radiological outcomes after two years of remission steered treatment in early arthritis patients","volume":"66","author":"Akdemir","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib330","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1136\/annrheumdis-2014-eular.2142","article-title":"ACPA-negative RA patients benefit from initial combination therapy with early clinical improvement-a sub-analysis of the best study","volume":"73","author":"Akdemir","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib331","doi-asserted-by":"publisher","first-page":"e000172","DOI":"10.1136\/rmdopen-2015-000172","article-title":"Predictive factors of radiological progression after 2 years of remission-steered treatment in early arthritis patients: a post hoc analysis of the IMPROVED study","volume":"2","author":"Akdemir","year":"2016","journal-title":"RMD Open"},{"key":"key20181204135736878_ref1-bib332","first-page":"953","article-title":"The impact of reaching low disease activity in the first year on future disability and damage in patients with early rheumatoid arthritis","volume":"40","author":"Akhavan","year":"2013","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib333","first-page":"1435","article-title":"Predictive validity of low disease activity using patient reported measures on long-term outcomes in early rheumatoid arthritis-results from study of new onset rheumatoid arthritis and Ontario best practices initiative","volume":"41","author":"Akhavan","year":"2014","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib334","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/acr.22678","article-title":"Effects of achieving target measures in rheumatoid arthritis on functional status, quality of life, and resource utilization: analysis of clinical practice data","volume":"68","author":"Alemao","year":"2016","journal-title":"Arthritis Care Res"},{"key":"key20181204135736878_ref1-bib335","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1136\/ard.2003.014647","article-title":"Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement","volume":"63","author":"Alessandri","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib336","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1002\/art.22943","article-title":"Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients","volume":"56","author":"Aletaha","year":"2007","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib337","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/art.24433","article-title":"Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment","volume":"60","author":"Aletaha","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib338","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/annrheumdis-2012-201970","article-title":"Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients","volume":"72","author":"Aletaha","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib339","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1136\/annrheumdis-2014-eular.4474","article-title":"Ultrasonography as useful tool to identify rheumatoid arthritis patients in clinical remission for tapering or withdrawal TNFa blockers without disease relapse","volume":"73","author":"Alivernini","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib340","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13075-016-0927-z","article-title":"Tapering and discontinuation of TNF-\u03b1 blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission","volume":"18","author":"Alivernini","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"key20181204135736878_ref1-bib341","first-page":"77","article-title":"Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study","volume":"24","author":"Allaart","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"key20181204135736878_ref1-bib342","first-page":"13","article-title":"When to start which DMARDs in rheumatoid arthritis?","volume":"39","author":"Allaart","year":"2010","journal-title":"Scand J Rheumatol"},{"key":"key20181204135736878_ref1-bib343","first-page":"24","article-title":"M-ficolin, an activator of the complement system, predicts DAS28 remission in early DMARD-naive rheumatoid arthritis","volume":"41","author":"Ammitzb\u00f8ll","year":"2012","journal-title":"Scand J Rheumatol"},{"key":"key20181204135736878_ref1-bib344","first-page":"S1065","article-title":"M-ficolin, an activator of the complement system, is the strongest predictor of both DAS28 remission and low disease activity in a cohort of 180 early DMARD naive rheumatoid arthritis patients followed in the opera-study","volume":"64","author":"Ammitzb\u00f8ll","year":"2012","journal-title":"Scand J Rheumatol"},{"key":"key20181204135736878_ref1-bib345","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1136\/annrheumdis-2012-eular.1906","article-title":"M-ficolin, an activator of the complement system, predicts DAS28 remission in early DMARD naive rheumatoid arthritis","volume":"71","author":"Ammitzb\u00f8ll","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib346","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1002\/art.38179","article-title":"M-ficolin levels reflect disease activity and predict remission in early rheumatoid arthritis","volume":"65","author":"Ammitzb\u00f8ll","year":"2013","journal-title":"Rheum Arthritis"},{"key":"key20181204135736878_ref1-bib347","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1136\/annrheumdis-2014-eular.2613","article-title":"Correlation between time to switch and clinical response amplitude to rituximab in second line treatment in rheumatoid arthritis patients with treatment failure to tumor necrosis factor inhibitors: 3-year data from repeat observational study","volume":"73","author":"Ancuta","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib348","first-page":"578","article-title":"Radiographic progression in the Cobra study: computer measurements of joint space, a comparison with scoring","volume":"65","author":"Angwin","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib349","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.autrev.2009.01.005","article-title":"Predicting response to anti-TNF treatment in rheumatoid arthritis patients","volume":"8","author":"Atzeni","year":"2009","journal-title":"Autoimmun Rev"},{"key":"key20181204135736878_ref1-bib350","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jbspin.2013.04.005","article-title":"Predictors of response to anti-TNF therapy in RA patients with moderate or high DAS28 scores","volume":"81","author":"Atzeni","year":"2014","journal-title":"Joint Bone Spine"},{"key":"key20181204135736878_ref1-bib351","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1007\/s10067-005-0136-7","article-title":"Severity of rheumatoid arthritis: the SEVERA study","volume":"25","author":"Baddoura","year":"2006","journal-title":"Clin Rheumatol"},{"key":"key20181204135736878_ref1-bib352","first-page":"1479","article-title":"Does low disease activity at six months predict remission at 12 months in rheumatoid arthritis patients treated with biologics in a real-world setting?","volume":"41","author":"Baer","year":"2014","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib353","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1136\/annrheumdis-2014-eular.5750","article-title":"Biomarker sets predict therapeutic response to TNF-inhibitors in rheumatoid arthritis and spondyloarthritis patients: a theragnostic approach in a multicenter cohort","volume":"73","author":"Baillet","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib354","first-page":"S93","article-title":"Comparison of DAS-28 and 2011-ACR\/EULAR remission criteria in a biologic-treated rheumatoid arthritis patient cohort","volume":"182","author":"Balogh","year":"2013","journal-title":"Ir J Med Sci"},{"key":"key20181204135736878_ref1-bib355","doi-asserted-by":"publisher","first-page":"R221","DOI":"10.1186\/ar4421","article-title":"Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder","volume":"15","author":"Balogh","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"key20181204135736878_ref1-bib356","unstructured":"Barnabe CCM, Homik J, Barr SG, Maksymowych WP, Martin L. Predictors for Remission in Rheumatoid Arthritis are Affected by Remission Definition. American College of Rheumatology\/Association of Rheumatology Health Professionals (ACR\/ARHP) Annual Scientific Meeting, Chicago, IL, 4\u20139 November 2011."},{"key":"key20181204135736878_ref1-bib357","first-page":"1734","article-title":"Identified predictors for remission in rheumatoid arthritis depend on remission definition","volume":"39","author":"Barnabe","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib358","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.3899\/jrheum.131451","article-title":"The effect of different remission definitions on identification of predictors of both point and sustained remission in rheumatoid arthritis treated with anti-TNF therapy","volume":"41","author":"Barnabe","year":"2014","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib359","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.dhjo.2013.04.008","article-title":"Factors associated with disability in a sample of adults with arthritis","volume":"6","author":"Baruth","year":"2013","journal-title":"Disabil Health J"},{"key":"key20181204135736878_ref1-bib360","first-page":"173","article-title":"Disease activity scores using CRP versus ESR and the relationship between EULAR and ACR responses in patients with early rheumatoid arthritis","volume":"64","author":"Bathon","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib361","first-page":"1532","article-title":"Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability","volume":"31","author":"Baumgartner","year":"2004","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib362","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/RHU.0000000000000150","article-title":"Serological biomarkers of joint tissue turnover predict tocilizumab response at baseline","volume":"20","author":"Bay-Jensen","year":"2014","journal-title":"J Clin Rheumatol"},{"key":"key20181204135736878_ref1-bib363","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/acr.20553","article-title":"Relationship between early bone mineral density changes and long-term function and radiographic progression in rheumatoid arthritis","volume":"64","author":"Bejarano","year":"2012","journal-title":"Arthritis Care Res"},{"key":"key20181204135736878_ref1-bib364","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/annrheumdis-2015-eular.4927","article-title":"Ultrasound-detected synovitis and tenosynovitis independently associate with flare in patients with rheumatoid arthritis in clinical remission","volume":"74","author":"Bellis","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib365","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1136\/annrheumdis-2014-eular.5807","article-title":"Comparison of activity score DAS28-ESR and DAS28-CRP in patients with rheumatoid arthritis","volume":"73","author":"Ben Slama","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib366","first-page":"2266","article-title":"Comparative effectiveness of biologic therapies for treating rheumatoid arthritis (RA) in patients who failed an anti tumor necrosis factor agent: a meta-regression analysis","volume":"62","author":"Benedict","year":"2010","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib367","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/BF02030966","article-title":"Influence of previous gold treatment and other patient variables on outcome of treatment with disease modifying anti-rheumatic drugs (DMARD) in patients with rheumatoid arthritis","volume":"5","author":"Bentzon","year":"1986","journal-title":"Clin Rheumatol"},{"key":"key20181204135736878_ref1-bib368","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.autrev.2010.07.006","article-title":"Predictive factors of response to rituximab therapy in rheumatoid arthritis: what do we know today?","volume":"9","author":"Benucci","year":"2010","journal-title":"Autoimmun Rev"},{"key":"key20181204135736878_ref1-bib369","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1136\/ard.2007.076463","article-title":"Optimal use of methotrexate: the advantages of tight control","volume":"66","author":"Bijlsma","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib370","first-page":"S558","article-title":"Predictors of significant Disease Activity Score-28 (using C-reactive protein) remission achieved with intravenous golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results of the phase 3, multicenter, double-blind, placebo-controlled trial","volume":"64","author":"Bingham","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib371","first-page":"82","article-title":"Predictors of significant Disease Activity Score-28 (using C-reactive protein) remission achieved with intravenous golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results of the phase iii, multicentre, double-blind, placebo-controlled trial","volume":"52","author":"Bingham","year":"2013","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib372","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1136\/ard.2006.060608","article-title":"High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis","volume":"66","author":"Bobbio-Pallavicini","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib373","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1002\/1529-0131(200110)44:10<2242::AID-ART386>3.0.CO;2-F","article-title":"Combinatietherapie Bij Reumatoide Artritis. Inflammation and damage in an individual joint predict further damage in that joint in patients with early rheumatoid arthritis","volume":"44","author":"Boers","year":"2001","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib374","first-page":"S33","article-title":"Ultrasound active synovitis can be predicted by using clinical measures","volume":"32","author":"Borangiu","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"key20181204135736878_ref1-bib375","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/annrheumdis-2015-eular.1932","article-title":"Associations of a multi-biomarker disease activity score with clinical and radiographic parameters in rheumatoid arthritis","volume":"74","author":"Bouman","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib376","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/art.23144","article-title":"Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial","volume":"58","author":"Braun","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib377","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1136\/ard.2003.017160","article-title":"Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis","volume":"64","author":"Breedveld","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib378","first-page":"S331\u2013S","article-title":"Baseline clinical, functional and ultrasonographic assessment can be used to predict subsequent remission in rheumatoid arthritis","volume":"46","author":"Brown","year":"2002","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib379","first-page":"S145\u2013S","article-title":"Does synovial cytokine expression predict response to tumour necrosis factor-alpha blockade in patients with rheumatoid arthritis?","volume":"48","author":"Buch","year":"2003","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib380","first-page":"15","article-title":"Basal metabolic rate as an indicator of rheumatoid arthritis disease activity and predictor of remission: Australian results from period 1 of the preserve trial","volume":"43","author":"Buchanan","year":"2013","journal-title":"Intern Med"},{"key":"key20181204135736878_ref1-bib381","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/art.23247","article-title":"Clinical remission and\/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study","volume":"59","author":"Burmester","year":"2008","journal-title":"Arthritis Care Res"},{"key":"key20181204135736878_ref1-bib382","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1136\/annrheumdis-2013-204769","article-title":"Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial","volume":"74","author":"Burmester","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib383","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1136\/annrheumdis-2015-eular.2071","article-title":"On drug and drug-free remission by baseline disease duration in the avert trial: abatacept versus methotrexate comparison in patients with early rheumatoid arthritis","volume":"74","author":"Bykerk","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib384","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1136\/ejhpharm-2013-000386","article-title":"Biological therapy for rheumatoid arthritis: is personalised medicine possible?","volume":"21","author":"Callaghan","year":"2014","journal-title":"Eur J Hosp Pharm Sci Pract"},{"key":"key20181204135736878_ref1-bib385","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/rheumatology\/keq381","article-title":"Clinical significance of high levels of soluble tumour necrosis factor-\u03b1 receptor-2 produced by alternative splicing in rheumatoid arthritis: a longitudinal prospective cohort study","volume":"50","author":"Ca\u00f1ete","year":"2011","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib386","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1093\/rheumatology\/kes184","article-title":"Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis","volume":"51","author":"Canh\u00e3o","year":"2012","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib387","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.semarthrit.2015.10.001","article-title":"Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis","volume":"45","author":"Cantini","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib388","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/ard.52.6.423","article-title":"Second line (disease modifying) treatment in rheumatoid arthritis: which drug for which patient?","volume":"52","author":"Capell","year":"1993","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib389","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.3899\/jrheum.141586","article-title":"Prediction of remission in a French early arthritis cohort by RAPID3 and other core data set measures, but not by the absence of rheumatoid factor, anticitrullinated protein antibodies, or radiographic erosions","volume":"43","author":"Castrej\u00f3n","year":"2016","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib390","doi-asserted-by":"publisher","first-page":"A880","DOI":"10.1136\/annrheumdis-2013-eular.2626","article-title":"Clinical and serological response to tocilizumab in patients with rheumatoid arthritis","volume":"72","author":"Casu","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib391","first-page":"1464","article-title":"Predicting radiographic progression in rheumatoid arthritis with ultrasound and biomarkers","volume":"60","author":"Cavet","year":"2009","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib392","first-page":"S1092","article-title":"Early response indicator early predicts clinical response to certolizumab in rheumatoid arthritis patients","volume":"66","author":"Cazzato","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib393","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4081\/reumatismo.2015.838","article-title":"Neutrophil-lymphocyte ratio, pain perception, and disease activity score may serve as important predictive markers for sustained remission in rheumatoid arthritis","volume":"67","author":"Chandrashekara","year":"2015","journal-title":"Reumatismo"},{"key":"key20181204135736878_ref1-bib394","first-page":"442","article-title":"Seropositivity and in particular ACPA positivity is a strong predictor of response to treatment with rituximab: pooled data from 10 European registries","volume":"69","author":"Chatzidionysiou","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib395","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1136\/annrheumdis-2012-eular.2051","article-title":"Seropositivity and response to RTX: data from the cererra collaboration","volume":"71","author":"Chatzidionysiou","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib396","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1136\/annrheumdis-2015-eular.5225","article-title":"Smoking and response to rituximab in anti-CCP positive and negative rheumatoid arthritis-results from an international European collaboration","volume":"74","author":"Chatzidionysiou","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib397","doi-asserted-by":"publisher","first-page":"e64862","DOI":"10.1371\/journal.pone.0064862","article-title":"Influence of adult height on rheumatoid arthritis: association with disease activity, impairment of joint function and overall disability","volume":"8","author":"Chen","year":"2013","journal-title":"PLOS ONE"},{"key":"key20181204135736878_ref1-bib398","doi-asserted-by":"publisher","first-page":"635293","DOI":"10.1155\/2014\/635293","article-title":"Elevated serum IgG4 defines specific clinical phenotype of rheumatoid arthritis","volume":"2014","author":"Chen","year":"2014","journal-title":"Mediators Inflamm"},{"key":"key20181204135736878_ref1-bib399","first-page":"S602","article-title":"Are tender joints better than synovitis to predict structural damage in rheumatoid arthritis?","volume":"66","author":"Cheung","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib400","first-page":"iii162","article-title":"Initial triple DMARD therapy predicts ACR EULAR remission in an early rheumatoid arthritis inception cohort","volume":"51","author":"Chitale","year":"2012","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib401","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.semarthrit.2012.02.004","article-title":"Do patients with elderly-onset rheumatoid arthritis have severe functional disability?","volume":"42","author":"Cho","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib402","first-page":"1323","article-title":"Impact of disease duration on the outcome of RA patients treated with infliximab in Canada","volume":"37","author":"Choquette","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib403","doi-asserted-by":"crossref","unstructured":"Choquette D, Bensen WG, Sheriff MK, Kelsall JT, Baker MF, Sampalis JS, et al. Comparison of Disease Characteristics of Rheumatoid Arthritis Patients in Remission According to the DAS Criteria Versus the New ACR\/EULAR Criteria in a Real-World Patient Population. American College of Rheumatology\/Association of Rheumatology Health Professionals (ACR\/ARHP) Annual Scientific Meeting, Chicago, IL, 4\u20139 November 2011.","DOI":"10.1136\/annrheumdis-2012-eular.2520"},{"key":"key20181204135736878_ref1-bib404","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1136\/annrheumdis-2012-eular.2520","article-title":"Comparison of disease characteristics of RA patients in remission according to the DAS criteria versus the new ACR\/EULAR criteria in a real-world patient population","volume":"71","author":"Choquette","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib405","first-page":"965","article-title":"What is the impact of rheumatoid factor positivity on the real-world effectiveness of infliximab treatment in rheumatoid arthritis?","volume":"40","author":"Choquette","year":"2013","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib406","article-title":"Use of rituximab compared to anti-TNF agents as second and third line therapy in patients with rheumatoid arthritis: 6-year follow-up report from the rhumadata clinical database and registry","volume":"67","author":"Choquette","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib407","first-page":"1346","article-title":"Predictors of clinical response to biologics in rheumatoid arthritis: experience from a Canadian clinic","volume":"42","author":"Choquette","year":"2015","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib408","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/annrheumdis-2015-eular.6199","article-title":"What is the effect of TNF inhibitors on employment status in rheumatoid arthritis patients and what are the predictors of progression to unemployment?","volume":"42","author":"Chow","year":"2015","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib409","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/ncprheum0533","article-title":"Does the Health Assessment Questionnaire predict 5-year quality of life in early RA?","volume":"3","author":"Choy","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"key20181204135736878_ref1-bib410","doi-asserted-by":"publisher","first-page":"A384","DOI":"10.1136\/annrheumdis-2013-eular.1177","article-title":"Physician global assessment at three months is strongly predictive of disease activity at 12 months in early rheumatoid arthritis. Results from the catch cohort","volume":"72","author":"Choy","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib411","doi-asserted-by":"publisher","first-page":"e004313","DOI":"10.1136\/bmjopen-2013-004313","article-title":"Temporal summation of pain and ultrasound Doppler activity as predictors of treatment response in patients with rheumatoid arthritis: protocol for the Frederiksberg hospitals Rheumatoid Arthritis, pain assessment and Medical Evaluation (FRAME-cohort) study","volume":"4","author":"Christensen","year":"2014","journal-title":"BMJ Open"},{"key":"key20181204135736878_ref1-bib412","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/rheumatology\/kew034","article-title":"Ultrasound Doppler but not temporal summation of pain predicts DAS28 response in rheumatoid arthritis: a prospective cohort study","volume":"55","author":"Christensen","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"key20181204135736878_ref1-bib413","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1136\/annrheumdis-2015-eular.1886","article-title":"Evaluating impact of risk associated outcomes on ultrasound Doppler score of patients with inflammatory hand joint pain using a beta-binomial model","volume":"74","author":"Ciurtin","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib414","unstructured":"Coburn B, Thiele GM, Duryee MJ, Yu F, Sayles H, Sokolove J, et al. Anti-citrullinated Protein Antibody and Radiographic Disease Progression in Rheumatoid Arthritis. Paper presented at the 2015 ACR\/ARHP Annual Meeting, San Francisco, CA, September 2015."},{"key":"key20181204135736878_ref1-bib415","first-page":"437","article-title":"C-reactive protein predicts treatment response to adalimumab (HUMIRA\u00ae) in patients with rheumatoid arthritis","volume":"64","author":"Cohen","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib416","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10067-015-3154-0","article-title":"High rates of obesity and greater associated disability among people with rheumatoid arthritis in Canada","volume":"35","author":"Colmegna","year":"2016","journal-title":"Clin Rheumatol"},{"key":"key20181204135736878_ref1-bib417","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/acr.21865","article-title":"Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital","volume":"65","author":"Couderc","year":"2013","journal-title":"Arthritis Care Res"},{"key":"key20181204135736878_ref1-bib418","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ebiom.2016.08.024","article-title":"Rheumatoid arthritis patients after initiation of a new biologic agent: trajectories of disease activity in a large multinational cohort study","volume":"11","author":"Courvoisier","year":"2016","journal-title":"EBioMedicine"},{"key":"key20181204135736878_ref1-bib419","first-page":"1067","article-title":"Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis","volume":"26","author":"Cuchacovich","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"key20181204135736878_ref1-bib420","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1136\/annrheumdis-2015-eular.3815","article-title":"Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability","volume":"74","author":"Cuppen","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib421","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1136\/annrheumdis-2015-eular.3839","article-title":"Towards individualized risk determination in RA: a prediction model for TNFi discontinuation within the first year after start","volume":"74","author":"Cuppen","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib422","doi-asserted-by":"publisher","first-page":"e0163087","DOI":"10.1371\/journal.pone.0163087","article-title":"Exploring the inflammatory metabolomic profile to predict response to TNF-\u03b1 inhibitors in rheumatoid arthritis","volume":"11","author":"Cuppen","year":"2016","journal-title":"PLOS ONE"},{"key":"key20181204135736878_ref1-bib423","first-page":"1117","article-title":"Prediction of one-year response to etanercept and methotrexate in rheumatoid arthritis patients in TEMPO","volume":"62","author":"Curtis","year":"2010","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib424","doi-asserted-by":"publisher","first-page":"R155","DOI":"10.1186\/ar3471","article-title":"Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis","volume":"13","author":"Curtis","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"key20181204135736878_ref1-bib425","first-page":"S69","article-title":"Validation of a preliminary administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis","volume":"20","author":"Curtis","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key20181204135736878_ref1-bib426","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/acr.21600","article-title":"Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12 weeks associated with low disease activity at 1 year","volume":"64","author":"Curtis","year":"2012","journal-title":"Arthritis Care Res"},{"key":"key20181204135736878_ref1-bib427","doi-asserted-by":"publisher","first-page":"572","DOI":"10.3899\/jrheum.120715","article-title":"Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA: results from the TEAR Trial","volume":"40","author":"Curtis","year":"2013","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib428","first-page":"81","article-title":"Do ultrasound (power Doppler ultrasonography) and Disease Activity Score-28 measure different aspects of disease activity? Analyses from an open-label study of power Doppler ultrasonography response patients with rheumatoid arthritis patients starting abatacept","volume":"54","author":"D\u2019Agostino","year":"2015","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib429","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1136\/annrheumdis-2015-eular.1727","article-title":"In patients with rheumatoid arthritis and an inadequate response to methotrexate, does body mass index influence the efficacy of abatacept on inflammation when measured by power Doppler ultrasonography? Results from the appraise study","volume":"74","author":"D\u2019Agostino","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib430","first-page":"994","article-title":"TNF-inhibitors in established rheumatoid arthritis: the effect of age on treatment response and predictors of remission","volume":"60","author":"Dahl","year":"2009","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib431","first-page":"92","article-title":"The clinical response to etanercept in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor-alpha expression in the synovium","volume":"13","author":"Dai","year":"2010","journal-title":"Int J Rheum Dis"},{"key":"key20181204135736878_ref1-bib432","doi-asserted-by":"publisher","first-page":"386148","DOI":"10.1155\/2014\/386148","article-title":"Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine","volume":"2014","author":"Da\u00efen","year":"2014","journal-title":"Mediators Inflamm"},{"key":"key20181204135736878_ref1-bib433","first-page":"S187","article-title":"Utility of Disease Activity Score-28 (DAS-28) for determining need for DMARD change in veterans affairs rheumatoid arthritis (VARA) patients: an analysis of discrepancies between DAS-28 scores and clinical stability status","volume":"54","author":"Dames","year":"2006","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib434","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1007\/s00296-011-2261-8","article-title":"Baseline HAQ and SF-36 questionnaire scores cannot predict clinical remission, radiographic progression or the need for biological therapy in a three-year prospective study of a Brazilian early rheumatoid arthritis cohort","volume":"32","author":"da Mota","year":"2012","journal-title":"Rheumatol Int"},{"key":"key20181204135736878_ref1-bib435","article-title":"Male gender and higher hemoglobin predict response to methotrexate in rheumatoid arthritis","volume":"67","author":"Danve","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib436","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10067-014-2749-1","article-title":"The good EULAR response at the first year is strongly predictive of clinical remission in rheumatoid arthritis: results from the TARAC cohort","volume":"34","author":"Darawankul","year":"2015","journal-title":"Clin Rheumatol"},{"key":"key20181204135736878_ref1-bib437","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1136\/annrheumdis-2014-eular.2258","article-title":"Predictors of low disease activity and remission after one dose of golimumab in patients with rheumatoid arthritis","volume":"73","author":"Dasgupta","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib438","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00296-009-0978-4","article-title":"Third generation anti-cyclic citrullinated peptide antibodies do not predict anti-TNF-alpha treatment response in rheumatoid arthritis","volume":"30","author":"Dejaco","year":"2010","journal-title":"Rheumatol Int"},{"key":"key20181204135736878_ref1-bib439","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1136\/annrheumdis-2012-202152","article-title":"Response to glucocorticoids at 2 weeks predicts the effectiveness of DMARD induction therapy at 3 months: post hoc analyses from the tREACH study","volume":"72","author":"de Jong","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib440","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13075-015-0564-y","article-title":"Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab","volume":"17","author":"de Jong","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"key20181204135736878_ref1-bib441","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1136\/annrheumdis-2015-eular.5223","article-title":"Doppler ultrasound better predicts X-Ray progression in rheumatoid arthritis than any definition of clinical remission","volume":"74","author":"De Miguel","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib442","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/rheumatology\/keq230","article-title":"Predicting arthritis outcomes \u2013 what can be learned from the Leiden Early Arthritis Clinic?","volume":"50","author":"de Rooy","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"key20181204135736878_ref1-bib443","first-page":"398","article-title":"Value of wrist ultrasound in prediction of disease activity in patients with rheumatoid arthritis","volume":"62","author":"Demir","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib444","doi-asserted-by":"publisher","first-page":"i95","DOI":"10.1093\/rheumatology\/keu101.022","article-title":"Synovial ectopic lymphoneogenesis predicts primary clinical response to certolizumab pegol in patients with rheumatoid arthritis","volume":"53","author":"Di Cicco","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"key20181204135736878_ref1-bib445","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1136\/annrheumdis-2014-eular.5365","article-title":"Presence of synovial lymphocyte aggregates predicts clinical response to DMARD therapy in patients with early rheumatoid arthritis","volume":"73","author":"Di Cicco","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib446","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s10067-015-2973-3","article-title":"Predictors of response to TNF-\u03b1 antagonist therapy in Chinese rheumatoid arthritis","volume":"34","author":"Ding","year":"2015","journal-title":"Clin Rheumatol"},{"key":"key20181204135736878_ref1-bib447","first-page":"1192","article-title":"Predictors of HAQ response after 3 months of treatment with different strategies in recent onset active RA","volume":"60","author":"Dirven","year":"2009","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib448","first-page":"I99-I","article-title":"Sustained efficacy along with improvements in disease activity score 28 (DAS 28) and patient (Pt)-reported outcomes (PROs) with abatacept (Aba) in rheumatoid arthritis (RA) pts with an inadequate response to anti-tumor necrosis factor (TNF) therapy: the long-term extension (LTE) of the attain trial","volume":"46","author":"Dougados","year":"2007","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib449","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.3899\/jrheum.090838","article-title":"Predictors of clinical response and radiographic progression in patients with rheumatoid arthritis treated with methotrexate monotherapy","volume":"37","author":"Drouin","year":"2010","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib450","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1136\/annrheumdis-2014-eular.1699","article-title":"Baseline predictors of remission rates during golimumab treatment for rheumatoid arthritis in the go-more study","volume":"73","author":"Durez","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib451","first-page":"362","article-title":"The increased cc chemokine ligand 19 (CCL19) at baseline is an independent predictor of the 5-year radiographic progression in early steroid and DMARD-naive rheumatoid arthritis (RA) patients","volume":"60","author":"Ellingsen","year":"2009","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib452","first-page":"I41","article-title":"Abatacept inhibits structural damage progression, as assessed by the Genant-modified Sharp scoring system, in rheumatoid arthritis (RA) patients with an inadequate response to methotrexate (MTX): the aim (abatacept in inadequate responders to MTX) trial \u2013 a sub-analysis by disease duration","volume":"45","author":"Emery","year":"2006","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib453","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1136\/ard.2011.154500","article-title":"Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis","volume":"70","author":"Emery","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib454","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1136\/ard.2010.148015","article-title":"Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response","volume":"70","author":"Emery","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib455","first-page":"iii113","article-title":"Post-treatment changes in serum C-reactive protein levels and clinical response in rheumatoid arthritis","volume":"50","author":"Emery","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib456","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1136\/annrheumdis-2011-201066","article-title":"Combination etanercept and methotrexate provides better disease control in very early (\u2264\u20094 months) versus early rheumatoid arthritis (>\u20094 months and <\u20092 years): post hoc analyses from the COMET study","volume":"71","author":"Emery","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib457","first-page":"58","article-title":"Golimumab\u2019s efficacy in patients with very active disease in methotrexate-naive rheumatoid arthritis","volume":"15","author":"Emery","year":"2012","journal-title":"Int J Rheum Dis"},{"key":"key20181204135736878_ref1-bib458","first-page":"iii68","article-title":"Predictors of radiographic progression in methotrexate-naive patients with rheumatoid arthritis based on one-year radiographic data from the go-before golimumab clinical trial","volume":"51","author":"Emery","year":"2012","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib459","doi-asserted-by":"publisher","first-page":"A399","DOI":"10.1136\/annrheumdis-2013-eular.1217","article-title":"Radiographic progression in patients with early rheumatoid arthritis treated with etanercept: results from the prize study","volume":"72","author":"Emery","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib460","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/annrheumdis-2014-eular.1704","article-title":"Early response to etanercept-methotrexate induction therapy predicts sustained remission with reduced-dose combination regimen in the prize study","volume":"73","author":"Emery","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib461","first-page":"S1094","article-title":"Early response to full-dose etanercept-plus-methotrexate induction therapy predicts sustained remission with reduced-dose combination therapy in early rheumatoid arthritis patients","volume":"66","author":"Emery","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib462","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s10067-014-2731-y","article-title":"Efficacy of golimumab plus methotrexate in methotrexate-na\u00efve patients with severe active rheumatoid arthritis","volume":"33","author":"Emery","year":"2014","journal-title":"Clin Rheumatol"},{"key":"key20181204135736878_ref1-bib463","first-page":"S1084","article-title":"Predictors of drug-free remission following treatment with abatacept (in combination with methotrexate or as monotherapy) in early rheumatoid arthritis","volume":"66","author":"Emery","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib464","article-title":"Abatacept plus methotrexate can effectively and safely regain the target of remission following re-treatment for flares after drug-free withdrawal in patients with early rheumatoid arthritis","volume":"67","author":"Emery","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib465","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1007\/s00296-015-3312-3","article-title":"A European chart review study on early rheumatoid arthritis treatment patterns, clinical outcomes, and healthcare utilization","volume":"35","author":"Emery","year":"2015","journal-title":"Rheumatol Int"},{"key":"key20181204135736878_ref1-bib466","first-page":"S935","article-title":"Predictors of radiologic disease progression during the rheumatoid arthritis comparison of active therapies trial","volume":"66","author":"Erickson","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib467","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s00296-011-1822-1","article-title":"Extraarticular manifestations in Turkish patients with rheumatoid arthritis: impact of EAMs on the health-related quality of life in terms of disease activity, functional status, severity of pain, and social and emotional functioning","volume":"32","author":"Eser","year":"2012","journal-title":"Rheumatol Int"},{"key":"key20181204135736878_ref1-bib468","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1002\/art.11335","article-title":"Swollen joint count as a predictor of response to anti-tumor necrosis factor alpha therapy in rheumatoid arthritis: comment on the article by Sokka and Pincus (multiple letters) [3]","volume":"48","author":"Estrach","year":"2003","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib469","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1136\/annrheumdis-2015-eular.2100","article-title":"Predictability to achieve low activity and\/or remission with leflunomide use in patients with rheumatoid arthritis","volume":"74","author":"Fabricio","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib470","first-page":"253","article-title":"Study on the possible role of the \u2013174G>C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis","volume":"62","author":"Fabris","year":"2010","journal-title":"Reumatismo"},{"key":"key20181204135736878_ref1-bib471","first-page":"S158","article-title":"Moderate rheumatoid arthritis despite methotrexate treatment: risk of radiographic progression","volume":"64","author":"Fautrel","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib472","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1136\/annrheumdis-2014-206696","article-title":"Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study)","volume":"75","author":"Fautrel","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib473","doi-asserted-by":"publisher","first-page":"A214","DOI":"10.1136\/annrheumdis-2013-eular.679","article-title":"Disease duration and year of publication affect the results of studies on rheumatoid arthritis damage progression by biologic agents: a systematic review and meta-analysis","volume":"72","author":"Favalli","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib474","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.semarthrit.2013.11.006","article-title":"The comparison of effects of biologic agents on rheumatoid arthritis damage progression is biased by period of enrollment: data from a systematic review and meta-analysis","volume":"43","author":"Favalli","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib475","article-title":"Clinical parameters and B cell subsets as biomarkers of response to tocilizumab in rheumatoid arthritis","volume":"67","author":"Fedele","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib476","doi-asserted-by":"publisher","first-page":"A16","DOI":"10.1136\/annrheumdis-2013-205124.36","article-title":"Effects of four different treatment regimens on radiologic progression in early rheumatoid arthritis (RA)","volume":"73","author":"Fedorenko","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib477","first-page":"1788","article-title":"A study to evaluate the effectiveness and safety of the interleukin-6 (IL-6) receptor antagonist tocilizumab (TCZ) after 4 and 24 weeks in patients with active rheumatoid arthritis (RA) final effectiveness results of the TAMARA study","volume":"62","author":"Feist","year":"2010","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib478","unstructured":"Ferdousi T, Koenig A, Jones T. Disease Duration as a Determinate Factor of Disease Activity and Radiographic Progression in Rheumatoid Arthritis. Paper presented at the 2011 ACR\/ARHP Scientific Meeting, Chicago, IL, November 2011."},{"key":"key20181204135736878_ref1-bib479","first-page":"2334","article-title":"Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis","volume":"34","author":"Fern\u00e1ndez-Nebro","year":"2007","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib480","first-page":"i162","article-title":"Utility of ultrasound joint counts as predictors of outcome in patients with very early arthritis","volume":"49","author":"Filer","year":"2010","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib481","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1136\/annrheumdis-2015-eular.1908","article-title":"Predictors of persistence of power Doppler ultrasound synovitis in rheumatoid arthritis patients in clinical remission","volume":"74","author":"Filippi","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib482","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1136\/ard.2006.065060","article-title":"Cigarette smoking and radiographic progression in rheumatoid arthritis","volume":"66","author":"Finckh","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib483","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1136\/ard.2008.105064","article-title":"Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?","volume":"69","author":"Finckh","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib484","article-title":"The impact of tobacco smoking on the effectiveness of abatacept in rheumatoid arthritis: data from a pan European analysis of RA registries","volume":"67","author":"Finckh","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib485","first-page":"iii104","article-title":"Fine specificity of anti-citrullinated peptide antibodies is associated with response to anti-TNF agents in rheumatoid arthritis: results from the British society of rheumatology biologics register","volume":"50","author":"Fisher","year":"2011","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib486","doi-asserted-by":"publisher","first-page":"929","DOI":"10.3899\/jrheum.111315","article-title":"Heterogeneity of anticitrullinated peptide antibodies and response to anti-tumor necrosis factor agents in rheumatoid arthritis","volume":"39","author":"Fisher","year":"2012","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib487","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1093\/rheumatology\/keu235","article-title":"Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis","volume":"53","author":"Fleischmann","year":"2014","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib488","doi-asserted-by":"publisher","first-page":"322","DOI":"10.2119\/molmed.2016.00078","article-title":"Integration of known DNA, RNA and protein biomarkers provides prediction of anti-TNF response in rheumatoid arthritis: results from the COMBINE study","volume":"22","author":"Folkersen","year":"2016","journal-title":"Mol Med"},{"key":"key20181204135736878_ref1-bib489","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jbspin.2008.06.006","article-title":"Ultrasound and magnetic resonance imaging did not provide early assessment of biotherapy response in patients with rheumatoid arthritis","volume":"76","author":"Foltz","year":"2009","journal-title":"Joint Bone Spine"},{"key":"key20181204135736878_ref1-bib490","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1093\/rheumatology\/keu455","article-title":"Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register","volume":"54","author":"Forsblad-d\u2019Elia","year":"2015","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib491","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.2217\/pgs.12.83","article-title":"Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failure","volume":"13","author":"Fransen","year":"2012","journal-title":"Pharmacogenomics"},{"key":"key20181204135736878_ref1-bib492","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1136\/annrheumdis-2014-eular.1980","article-title":"Predicting future response to tumor necrosis factor inhibitors by the distribution of affected joints in rheumatoid arthritis patients","volume":"73","author":"Fujimura","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib493","article-title":"Evaluation of patient-reported outcomes by baseline disease duration: 6-month data from two clinical trials of patients with early rheumatoid arthritis treated with abatacept","volume":"67","author":"Furst","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib494","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1093\/rheumatology\/kev249","article-title":"Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy","volume":"54","author":"Furst","year":"2015","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib495","first-page":"25","article-title":"Effect of TNF antagonists on the productivity of daily work of patients with rheumatoid arthritis","volume":"6","author":"Furuya","year":"2013","journal-title":"J Multidiscip Healthc"},{"key":"key20181204135736878_ref1-bib496","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.jbspin.2014.06.001","article-title":"High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis","volume":"81","author":"Gardette","year":"2014","journal-title":"Joint Bone Spine"},{"key":"key20181204135736878_ref1-bib497","doi-asserted-by":"publisher","first-page":"e000219","DOI":"10.1136\/rmdopen-2015-000219","article-title":"Association of the different types of radiographic damage with physical function in patients with rheumatoid arthritis: analysis of the RAPID trials","volume":"2","author":"Gherghe","year":"2016","journal-title":"RMD Open"},{"key":"key20181204135736878_ref1-bib498","first-page":"S562","article-title":"Mathematical model to predict the early responders in a monocentric cohort of patients with rheumatoid arthritis treated by anti TNFalpha","volume":"65","author":"Giacomelli","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib499","first-page":"589","article-title":"Factors associated with disease severity in Mexican patients with rheumatoid arthritis","volume":"12","author":"Glave-Testino","year":"1994","journal-title":"Clin Exp Rheumatol"},{"key":"key20181204135736878_ref1-bib500","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1185\/03007995.2010.549805","article-title":"Review of treatment response in rheumatoid arthritis: assessment of heterogeneity","volume":"27","author":"Goetz","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"key20181204135736878_ref1-bib501","first-page":"201","article-title":"High titers of anti-CCP antibodies at baseline and after one year of DMARDs may predict a poor clinical response in patients with early rheumatoid arthritis","volume":"63","author":"Gomez","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib502","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1136\/ard.2007.071910","article-title":"Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists","volume":"66","author":"Gonz\u00e1lez-Alvaro","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib503","doi-asserted-by":"publisher","first-page":"536050","DOI":"10.1155\/2014\/536050","article-title":"Anti-cyclic citrullinated peptide (anti-CCP) and anti-mutated citrullinated vimentin (anti-MCV) relation with extra-articular manifestations in rheumatoid arthritis","volume":"2014","author":"Gonzalez-Lopez","year":"2014","journal-title":"J Immunol Res"},{"key":"key20181204135736878_ref1-bib504","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1136\/annrheumdis-2015-eular.1973","article-title":"Body mass index is an independent risk factor for not achieving sustained remission in early rheumatoid arthritis: results from the catch observational study","volume":"74","author":"Goodman","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib505","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1136\/annrheumdis-2011-200975","article-title":"Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort","volume":"71","author":"Gottenberg","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib506","first-page":"47","article-title":"Inflammatory patterns in rheumatoid arthritis estimated by the number of swollen and tender joints, the erythrocyte sedimentation rate, and hemoglobin: longterm course and association to radiographic progression","volume":"27","author":"Graudal","year":"2000","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib507","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1136\/annrheumdis-2012-201456","article-title":"Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study","volume":"72","author":"Gremese","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib508","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1136\/annrheumdis-2015-eular.4712","article-title":"Clinical and B cell subsets biomarkers of response to tocilizumab in rheumatoid arthritis","volume":"74","author":"Gremese","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib509","first-page":"iii74","article-title":"Predicting ongoing active disease in early rheumatoid arthritis using clinical measures","volume":"51","author":"Gullick","year":"2012","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib510","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/BF02206657","article-title":"Rheumatoid nodules do not predict response to treatment with slow-acting anti-rheumatic drugs","volume":"10","author":"Hall","year":"1991","journal-title":"J Clin Rheumtol"},{"key":"key20181204135736878_ref1-bib511","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s00296-011-1802-5","article-title":"Power Doppler ultrasonography is useful for assessing disease activity and predicting joint destruction in rheumatoid arthritis patients receiving tocilizumab \u2013 preliminary data","volume":"32","author":"Hama","year":"2012","journal-title":"Rheumatol Int"},{"key":"key20181204135736878_ref1-bib512","first-page":"S53","article-title":"PD signal detected by ultrasonography relates to joint destruction in rheumatoid arthritis under biologics therapy in real world","volume":"66","author":"Hama","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib513","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1136\/annrheumdis-2015-eular.2542","article-title":"Wrist PD signal detected by ultrasonography relates to joint destruction in rheumatoid arthritis under biologics therapy in real world","volume":"74","author":"Hama","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"key20181204135736878_ref1-bib514","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/acr.23016","article-title":"Factors associated with sustained remission in rheumatoid arthritis in patients treated with anti-tumour necrosis factor (anti-TNF)","volume":"69","author":"Hamann","year":"2017","journal-title":"Arthritis Care Res"},{"key":"key20181204135736878_ref1-bib515","article-title":"Predictive biomarkers for response or non-response to MTX monotherapy in early RA","volume":"67","author":"Hambardzumyan","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib516","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1136\/ard.2009.126995","article-title":"A 78-joints ultrasonographic assessment is associated with clinical assessments and is highly responsive to improvement in a longitudinal study of patients with rheumatoid arthritis starting adalimumab treatment","volume":"69","author":"Hammer","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib517","unstructured":"Hammer HB, Birkelund B, Kvien TK. Patients with Rheumatoid Arthritis on Anti-TNF Therapy; Responders with Major Reduction in Power Doppler Activity Can Be Identified After One Month. American College of Rheumatology\/Association of Rheumatology Health Professionals (ACR\/ARHP) Annual Scientific Meeting, Chicago, IL, 4\u20139 November 2011."},{"key":"key20181204135736878_ref1-bib518","first-page":"S913","article-title":"Correlation of a multi-biomarker disease activity response assessment to disease activity score 28 (C-reactive protein) response assessment and OMERACT RAMRIS scores in a placebo-controlled rheumatoid arthritis clinical trial with abatacept (ASSET)","volume":"64","author":"Haney","year":"2012","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib519","first-page":"139","article-title":"Tailor-made therapy in rheumatoid arthritis: fact or fiction?","volume":"10","author":"Haroon","year":"2008","journal-title":"Isr Med Assoc J"},{"key":"key20181204135736878_ref1-bib520","first-page":"S175","article-title":"Can we improve outcomes in early rheumatoid arthritis by determining best practices? An analysis of the Canadian early rheumatoid arthritis cohort (CATCH)","volume":"64","author":"Harris","year":"2012","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib521","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1136\/annrheumdis-2012-eular.2535","article-title":"Can we improve outcomes in early rheumatoid arthritis (ERA) by determining best practices? An analysis of the Canadian era cohort (CATCH)","volume":"71","author":"Harris","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib522","article-title":"Enhancing comparative effectiveness research by combining observational and randomized trial data to personalize the choice between methotrexate and triple therapy for methotrexate-naive patients with early rheumatoid arthritis","volume":"67","author":"Hazlewood","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib523","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1479-8077.2007.00250.x","article-title":"The value of changes in CRP and ESR for predicting treatment response in rheumatoid arthritis","volume":"10","author":"Heidari","year":"2007","journal-title":"APLAR J Rheumatol"},{"key":"key20181204135736878_ref1-bib524","article-title":"Body mass index is associated with decreased response to initial and delayed treatment with dose escalated infliximab in patients with recent onset rheumatoid arthritis","volume":"63","author":"Heimans","year":"2011","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib525","first-page":"S611","article-title":"Predictive factors of response to tocilizumab in patients with active rheumatoid arthritis","volume":"65","author":"Hernandez","year":"2013","journal-title":"Clin Rheumatolo"},{"key":"key20181204135736878_ref1-bib526","article-title":"Efficacy of tocilizumab monotherapy in patients with RA is not influenced by ACPA positivity","volume":"67","author":"Herold","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib527","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1136\/ard.2009.125534","article-title":"Radiographic progression and remission rates in early rheumatoid arthritis \u2013 MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial","volume":"69","author":"Hetland","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib528","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1136\/annrheumdis-2015-eular.1247","article-title":"Predictors of effectiveness in golimumab treatment and efficacy of dose-escalation of golimumab in patients with rheumatoid arthritis\u2013a multicenter registry study TBCR","volume":"74","author":"Hirano","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib529","first-page":"S616","article-title":"Repeated high or low multi-biomarker disease activity (Vectra\u00ae DA algorithm) scores associated with radiographic outcomes in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors","volume":"65","author":"Hirata","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib530","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13075-015-0799-7","article-title":"Serum 14-3-3\u03b7 level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab","volume":"17","author":"Hirata","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"key20181204135736878_ref1-bib531","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/ard.62.5.423","article-title":"Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis","volume":"62","author":"Hoekstra","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib532","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/rheumatology\/kew037","article-title":"Discordance between the predictors of clinical and imaging remission in patients with early rheumatoid arthritis in clinical practice: implications for the use of ultrasound within a treatment-to-target strategy","volume":"55","author":"Horton","year":"2016","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib533","first-page":"S482","article-title":"Greater physical dysfunction is a negative predictor for achieving Boolean-based remission in patients with rheumatoid arthritis treated with tocilizumab","volume":"63","author":"Hoshi","year":"2011","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib534","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1177\/0091270010372520","article-title":"Population approach for exposure-response modeling of golimumab in patients with rheumatoid arthritis","volume":"51","author":"Hu","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"key20181204135736878_ref1-bib535","first-page":"140","article-title":"Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progression \u2013 Commentary","volume":"9","author":"Huizinga","year":"2011","journal-title":"Int J Adv Rheumatol"},{"key":"key20181204135736878_ref1-bib536","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1093\/rheumatology\/kev211","article-title":"Power Doppler ultrasound monitoring of response to anti-tumour necrosis factor alpha treatment in patients with rheumatoid arthritis","volume":"54","author":"Iagnocco","year":"2015","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib537","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1093\/rheumatology\/keq263","article-title":"Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women\u2019s Hospital Rheumatoid Arthritis Sequential Study","volume":"50","author":"Iannaccone","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"key20181204135736878_ref1-bib538","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1136\/annrheumdis-2012-eular.465","article-title":"Etanercept therapy in rheumatoid arthritis patients with moderate or severe disease activity","volume":"71","author":"Iannone","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib539","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1136\/annrheumdis-2015-eular.2487","article-title":"Early good EULAR response predicts low\/remission disease state in rheumatoid arthritis patients on treatment with certolizumab in real life settings. Data from Italian registry GISEA","volume":"74","author":"Iannone","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib540","doi-asserted-by":"publisher","first-page":"iii93","DOI":"10.1093\/rheumatology\/ker029","article-title":"Predictors of joint damage in South Africans with rheumatoid arthritis","volume":"50","author":"Ickinger","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"key20181204135736878_ref1-bib541","doi-asserted-by":"publisher","first-page":"R76","DOI":"10.1186\/ar1943","article-title":"Bone erosions in rheumatoid arthritis can be repaired through reduction in disease activity with conventional disease-modifying antirheumatic drugs","volume":"8","author":"Ideguchi","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"key20181204135736878_ref1-bib542","first-page":"S1200","article-title":"Can ultrasonographic findings predict response to tumor necrosis factor-alpha inhibitor treatment in rheumatoid arthritis?","volume":"65","author":"Inanc","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib543","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1136\/annrheumdis-2014-eular.1918","article-title":"Ultrasonographic assessment of joint inflammation in rheumatoid arthritis: predictive value in response to tumor necrosis factor-a inhibitor treatment","volume":"32","author":"Inanc","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"key20181204135736878_ref1-bib544","doi-asserted-by":"crossref","first-page":"A544","DOI":"10.1136\/annrheumdis-2013-eular.1630","article-title":"Ultrasonographic assessment of joint inflammation in rheumatoid arthritis: predictive value in response to tumor necrosis factor-alpha inhibitor treatment","volume":"72","author":"Inanc","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib545","first-page":"156","article-title":"Predictive value of ultrasonographic assessment of disease activity in response to tumor necrosis factor-\u03b1 inhibitor treatment in rheumatoid arthritis: a prospective cohort study","volume":"34","author":"Inanc","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"key20181204135736878_ref1-bib546","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1248\/yakushi.129.843","article-title":"Preliminary study to identify the predictive factors for the response to methotrexate therapy in patients with rheumatoid arthritis","volume":"129","author":"Inoue","year":"2009","journal-title":"Yakugaku Zasshi"},{"key":"key20181204135736878_ref1-bib547","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.3899\/jrheum.140376","article-title":"Effect of smoking on remission proportions differs between male and female patients with rheumatoid arthritis: a study based on the IORRA Survey","volume":"42","author":"Inoue","year":"2015","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib548","first-page":"442","article-title":"Autoantibody-positive rheumatoid arthritis (RA) patients (pts) have enhanced clinical response to rituximab (RTX) when compared with seronegative patients","volume":"68","author":"Isaacs","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib549","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/annrheumdis-2011-201117","article-title":"Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis","volume":"72","author":"Isaacs","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"key20181204135736878_ref1-bib550","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/14397595.2016.1206507","article-title":"Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study","volume":"27","author":"Ishiguro","year":"2017","journal-title":"Mod Rheumatol"},{"key":"key20181204135736878_ref1-bib551","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s10165-009-0187-8","article-title":"Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population","volume":"19","author":"Iwamoto","year":"2009","journal-title":"Mod Rheumatol"},{"key":"key20181204135736878_ref1-bib552","doi-asserted-by":"publisher","first-page":"662","DOI":"10.3109\/14397595.2015.1129692","article-title":"Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis","volume":"26","author":"Iwamoto","year":"2016","journal-title":"Mod Rheumatol"},{"key":"key20181204135736878_ref1-bib553","doi-asserted-by":"publisher","first-page":"e0145468","DOI":"10.1371\/journal.pone.0145468","article-title":"Baseline serum osteopontin levels predict the clinical effectiveness of tocilizumab but not infliximab in biologic-naive patients with rheumatoid arthritis: a single-center prospective study at 1 year (the Keio First-Bio Cohort Study)","volume":"10","author":"Izumi","year":"2015","journal-title":"PLOS ONE"},{"key":"key20181204135736878_ref1-bib554","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/ard.60.10.924","article-title":"Predictors of radiographic joint damage in patients with early rheumatoid arthritis","volume":"60","author":"Jansen","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib555","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3899\/jrheum.110548","article-title":"Sex differences in response to anti-tumor necrosis factor therapy in early and established rheumatoid arthritis \u2013 results from the DANBIO registry","volume":"39","author":"Jawaheer","year":"2012","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib556","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/rheumatology\/ker250","article-title":"Sustained clinical remission in rheumatoid arthritis: prevalence and prognostic factors in an inception cohort of patients treated with conventional DMARDS","volume":"51","author":"Jayakumar","year":"2012","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib557","article-title":"Does computerized segmentation of early erosions on magnetic resonance imaging predict functional ability in rheumatoid arthritis?","volume":"67","author":"Jessome","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib558","doi-asserted-by":"publisher","first-page":"728610","DOI":"10.1155\/2015\/728610","article-title":"The role of citrullinated protein antibodies in predicting erosive disease in rheumatoid arthritis: a systematic literature review and meta-analysis","volume":"2015","author":"Jilani","year":"2015","journal-title":"Int J Rheumatol"},{"key":"key20181204135736878_ref1-bib559","first-page":"1367","article-title":"Factors predicting outcome in rheumatoid arthritis","volume":"21","author":"Jones","year":"1994","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib560","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1136\/annrheumdis-2015-eular.5737","article-title":"Clinical predictors of severe radiographic damage in Korean patients with rheumatoid arthritis","volume":"74","author":"Joo","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib561","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1136\/annrheumdis-2014-eular.4125","article-title":"Contribution of the individual components of the disease activity score (DAS28) to the total DAS28 score among responders and non-responders to biological therapy for rheumatoid arthritis","volume":"73","author":"Jurgens","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib562","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/acr.22532","article-title":"Contribution of the subjective components of the disease activity score to the response to biologic treatment in rheumatoid arthritis","volume":"67","author":"Jurgens","year":"2015","journal-title":"Arthritis Care Res"},{"key":"key20181204135736878_ref1-bib563","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1136\/annrheumdis-2012-eular.3078","article-title":"Continuation\/discontinuation of methotrexate and clinical response to etanercept determine the radiographic progression\/repair in patients with rheumatoid arthritis: a subanalysis of 52-week results from the JESMR study","volume":"71","author":"Kameda","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib564","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1136\/annrheumdis-2012-201804","article-title":"A merged presentation of clinical and radiographic data using probability plots in a clinical trial, the JESMR study","volume":"72","author":"Kameda","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib565","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1136\/annrheumdis-2012-eular.515","article-title":"Predictors of clinical remission (DAS28CRP<2.6) in patients with RA who were treated with abatacept","volume":"71","author":"Kaneko","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib566","article-title":"Highly elevated rheumatoid factor is a risk factor for abatacept treatment failure in Japanese patients with rheumatoid arthritis","volume":"67","author":"Kaneshita","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib567","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1093\/rheumatology\/ket492","article-title":"What drives the comparative effectiveness of biologics vs. methotrexate in rheumatoid arthritis? Meta-regression and graphical inspection of suspected clinical factors","volume":"53","author":"Kanters","year":"2014","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib568","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1136\/annrheumdis-2015-eular.5277","article-title":"Dynamics of disease activity scores during the first 12 weeks allow to predict the necessity in combination therapy with methotrexate and biologics within T2T strategy in patients with early and established rheumatoid arthritis (REMARCA study)","volume":"74","author":"Karateev","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib569","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/acr.20188","article-title":"Predictors for remission in rheumatoid arthritis patients: a systematic review","volume":"62","author":"Katchamart","year":"2010","journal-title":"Arthritis Care Res"},{"key":"key20181204135736878_ref1-bib570","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.3899\/jrheum.151462","article-title":"Predictors of biological antirheumatic drug discontinuation in patients with rheumatoid arthritis while in remission","volume":"43","author":"Kawada","year":"2016","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib571","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1007\/s10165-012-0822-7","article-title":"Shorter disease duration is important for tocilizumab to achieve Boolean remission","volume":"23","author":"Kawasaki","year":"2013","journal-title":"Mod Rheumatol"},{"key":"key20181204135736878_ref1-bib572","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1136\/annrheumdis-2012-eular.574","article-title":"Evaluation of the efficacy of tocilizumab toward the patients with active rheumatoid arthritis of Nagasaki Prefecture, Japan","volume":"71","author":"Kawashiri","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib573","first-page":"445","article-title":"Baseline low modified health assessment questionnaire (MHAQ) predicts the state of remission estimated by clinical disease activity index and MHAQ at 1 year in tocilizumab-treated rheumatoid arthritis patients","volume":"32","author":"Kawashiri","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"key20181204135736878_ref1-bib574","doi-asserted-by":"publisher","first-page":"R40","DOI":"10.1186\/ar4469","article-title":"Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year","volume":"16","author":"Kay","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"key20181204135736878_ref1-bib575","first-page":"406","article-title":"Real life treatment with rituximab in TNF blocker non-responders is superior to treatment with a second TNF blocker","volume":"62","author":"Kekow","year":"2010","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib576","first-page":"iii41","article-title":"Smoking and rheumatoid factor status in predicting responses to biologics","volume":"51","author":"Khan","year":"2012","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib577","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s10067-016-3220-2","article-title":"No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study","volume":"35","author":"Kim","year":"2016","journal-title":"Clin Rheumatol"},{"key":"key20181204135736878_ref1-bib578","doi-asserted-by":"publisher","first-page":"676","DOI":"10.3109\/14397595.2015.1132952","article-title":"Time lag between the initiation of adalimumab after methotrexate correlates with the efficacy of adalimumab in rheumatoid arthritis patients","volume":"26","author":"Kimura","year":"2016","journal-title":"Mod Rheumatol"},{"key":"key20181204135736878_ref1-bib579","first-page":"1604","article-title":"Is the response to infliximab influenced by body mass index in rheumatoid arthritis patients?","volume":"60","author":"Klaasen","year":"2009","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib580","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1002\/art.24913","article-title":"The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study","volume":"60","author":"Klaasen","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib581","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/art.30136","article-title":"Body mass index and clinical response to infliximab in rheumatoid arthritis","volume":"63","author":"Klaasen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib582","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s00296-010-1784-8","article-title":"Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis","volume":"32","author":"Koike","year":"2012","journal-title":"Rheumatol Int"},{"key":"key20181204135736878_ref1-bib583","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3899\/jrheum.130466","article-title":"Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan","volume":"41","author":"Koike","year":"2014","journal-title":"J Rheumatol"},{"issue":"3","key":"key20181204135736878_ref1-bib584","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3109\/s10165-011-0528-2","article-title":"Early aggressive intervention for rheumatoid arthritis increases rate of remission defined using a Boolean approach in clinical practice with tocilizumab","volume":"22","author":"Kojima","year":"2012","journal-title":"Mod Rheumatol"},{"key":"key20181204135736878_ref1-bib585","doi-asserted-by":"publisher","first-page":"A628","DOI":"10.1136\/annrheumdis-2013-eular.1865","article-title":"Importance of concomitant MTX use during treatment with tocilizumab in patients with rheumatoid arthritis","volume":"72","author":"Kojima","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib586","first-page":"S629","article-title":"Relationship between physicians\u2019 decision to use concomitant glucocorticoid and remission during treatment with tocilizumab in patients with background of limited dose of MTX","volume":"65","author":"Kojima","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib587","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/rheumatology\/keu302","article-title":"Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study","volume":"54","author":"Kojima","year":"2015","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib588","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1136\/annrheumdis-2015-eular.1318","article-title":"Importance of both disease activity at 12 weeks and clinical response up to 12 weeks to predict achievement of low disease activity at 52 weeks during abatacept treatment in biologics-switching patients with rheumatoid arthritis: a multicenter observational cohort study in Japan","volume":"74","author":"Kojima","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"key20181204135736878_ref1-bib589","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10067-015-3135-3","article-title":"Predictive factors for achieving low disease activity at 52 weeks after switching from tumor necrosis factor inhibitors to abatacept: Results from a multicenter observational cohort study of Japanese patients","volume":"35","author":"Kojima","year":"2016","journal-title":"Clin Rheumatol"},{"key":"key20181204135736878_ref1-bib590","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1136\/annrheumdis-2012-eular.330","article-title":"Characteristics of a moderate rheumatoid arthritis patient population who lost remission or low disease activity: data from the Consortium of Rheumatology Researchers of North America, Inc. (CORRONA)","volume":"71","author":"Kotak","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib591","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1007\/s00296-011-2037-1","article-title":"An association study of disease activity score components and patient satisfaction with overall health for early RA patients on non-biologic DMARD therapy","volume":"32","author":"Kovalchik","year":"2012","journal-title":"Rheumatol Int"},{"key":"key20181204135736878_ref1-bib592","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/rheumatology\/ken002","article-title":"Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register","volume":"47","author":"Kristensen","year":"2008","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib593","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1002\/art.39627","article-title":"Brief report: predicting functional disability: one-year results from the Scottish early rheumatoid arthritis inception cohort","volume":"68","author":"Kronisch","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib594","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1007\/s00296-011-2317-9","article-title":"Reduction in sickness absence in patients with rheumatoid arthritis receiving adalimumab: data from a German noninterventional study","volume":"32","author":"Kr\u00fcger","year":"2012","journal-title":"Rheumatol Int"},{"key":"key20181204135736878_ref1-bib595","first-page":"13","article-title":"Rheumatoid arthritis: clinical spectrum, diagnosis and management","volume":"15","author":"Kumar","year":"2002","journal-title":"Int Med Sci Acad"},{"key":"key20181204135736878_ref1-bib596","first-page":"S912","article-title":"Anti-cyclic citrullinated protein antibodies as a predictor of response to tocilizumab in patients with rheumatoid arthritis a prospective study","volume":"64","author":"Kume","year":"2012","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib597","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.3899\/jrheum.140137","article-title":"Earlier time to remission predicts sustained clinical remission in early rheumatoid arthritis \u2013 results from the Canadian Early Arthritis Cohort (CATCH)","volume":"41","author":"Kuriya","year":"2014","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib598","first-page":"1272","article-title":"Working status and improvements in work productivity over time in an early rheumatoid arthritis (ERA) cohort","volume":"42","author":"Kuriya","year":"2015","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib599","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1136\/annrheumdis-2014-eular.4286","article-title":"Delay in RA diagnosis of more than 12 months is associated with deteriorated functional status in patients in bDMARD treatment-results from a prospective study","volume":"73","author":"Kynde","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib600","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/S0002-9343(01)00872-5","article-title":"Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies","volume":"111","author":"Lard","year":"2001","journal-title":"Am J Med"},{"key":"key20181204135736878_ref1-bib601","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1136\/annrheumdis-2014-eular.3292","article-title":"Progressive spacing tocilizumab infusions after remission in rheumatoid arthritis: the absence of erosion would be determinant in choosing this strategy","volume":"73","author":"Le Blay","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib602","first-page":"S773","article-title":"Disease Activity Score (DAS) and Health Assessment Questionnaire (HAQ) values show similar changes from baseline to endpoint in clinical trials of biological agents in patients with rheumatoid arthritis (RA)","volume":"58","author":"Lee","year":"2008","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib603","first-page":"S1145","article-title":"Application of a multi-biomarker disease activity (Vectra\u00ae DA) score for assessing rheumatoid arthritis patients with fibromyalgia or low c-reactive protein","volume":"65","author":"Lee","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib604","doi-asserted-by":"crossref","first-page":"A444","DOI":"10.1136\/annrheumdis-2013-eular.1338","article-title":"Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy","volume":"72","author":"Li","year":"2013","journal-title":"Int J Rheum Dis"},{"key":"key20181204135736878_ref1-bib605","first-page":"342","article-title":"Predictors of response to methotrexate treatment: results from a longitudinal observational study of 876 patients with RA","volume":"65","author":"Lie","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib606","article-title":"Characterization of long-term responders to first treatment course of rituximab (RTX) results from the CERERRA collaboration","volume":"63","author":"Lie","year":"2011","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib607","article-title":"Early versus delayed retreatment with rituximab (RTX) in relation to long term clinical response data from the CERERRA collaboration","volume":"63","author":"Lie","year":"2011","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib608","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/rheumatology\/ker356","article-title":"Effectiveness of sulfasalazine and methotrexate in 1102 DMARD-naive patients with early RA","volume":"51","author":"Lie","year":"2012","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib609","doi-asserted-by":"publisher","first-page":"A835","DOI":"10.1136\/annrheumdis-2013-eular.2486","article-title":"The influence of clinical and genetic variables on methotrexate effectiveness in Portuguese rheumatoid arthritis patients","volume":"72","author":"Lima","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib610","article-title":"Impact of obesity on the disease course of rheumatoid arthritis","volume":"67","author":"Liu","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib611","first-page":"S330","article-title":"New assay generation for antibodies against modified and citrullinated peptides predicts poor response to TNF inhibitor therapy","volume":"63","author":"Ljung","year":"2011","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib612","first-page":"315","article-title":"Low rate of rheumatoid arthritis remission in real life: might predictive factors explain?","volume":"62","author":"Loppin","year":"2010","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib613","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1136\/ard.2009.119156","article-title":"Repair of erosions occurs almost exclusively in damaged joints without swelling","volume":"69","author":"Lukas","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib614","doi-asserted-by":"publisher","first-page":"e89442","DOI":"10.1371\/journal.pone.0089442","article-title":"The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNF\u03b1 agent treatment in patients with rheumatoid arthritis: a meta-analysis","volume":"9","author":"Lv","year":"2014","journal-title":"PLOS ONE"},{"key":"key20181204135736878_ref1-bib615","first-page":"i132","article-title":"HAQ and gender predict remission in early RA: experience in the Early Rheumatoid Arthritis Network (ERAN)","volume":"48","author":"Ma","year":"2009","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib616","first-page":"i62","article-title":"Predicting remission in trial of intensive therapy in early RA: HAQ and gender are key factors","volume":"48","author":"Ma","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib617","doi-asserted-by":"crossref","first-page":"A394","DOI":"10.1136\/annrheumdis-2013-eular.1202","article-title":"A multi-biomarker disease activity (Vectra\u2122 DA algorithm) score and components are associated with sustained clinical remission in rheumatoid arthritis: the REMIRA study","volume":"72","author":"Ma","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib618","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1136\/annrheumdis-2014-eular.2757","article-title":"Multi-biomarker disease activity (Vectra\u00ae DA algorithm) score is associated with power Doppler ultrasound in patients with rheumatoid arthritis in low disease activity state: the REMIRA cohort","volume":"73","author":"Ma","year":"2014","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib619","first-page":"8","article-title":"Ultrasonographic predictors for the development of joint damage in rheumatoid arthritis patients: a single joint prospective study","volume":"31","author":"Macchioni","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"key20181204135736878_ref1-bib620","first-page":"S351\u2013S","article-title":"Predictors of rheumatoid arthritis: quantitative and semiquantitative sonographic measurements of peripheral joints","volume":"64","author":"Machado","year":"2012","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib621","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1136\/ard.2007.084897","article-title":"Sex: a major predictor of remission as measured by 28-joint Disease Activity Score (DAS28) in early rheumatoid arthritis?","volume":"67","author":"Makinen","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib622","first-page":"1670","article-title":"Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study","volume":"34","author":"Mancarella","year":"2007","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib623","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/annrheumdis-2012-eular.3427","article-title":"Are TNF blocking agents associated with changes in work participation in patients with RA?","volume":"71","author":"Manders","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib624","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.3899\/jrheum.130878","article-title":"Determinants associated with work participation in patients with established rheumatoid arthritis taking tumor necrosis factor inhibitors","volume":"41","author":"Manders","year":"2014","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib625","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.semarthrit.2012.11.007","article-title":"Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: systematic review and meta-analysis (Provisional abstract)","volume":"43","author":"Maneiro","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib626","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1136\/annrheumdis-2012-eular.2536","article-title":"Rheumatoid factor as predictor of response to non TNF antagonist biologic therapies in rheumatoid arthritis: systematic review and meta-analysis","volume":"71","author":"Maneiro","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib627","unstructured":"Markusse I, Han K, Peeters A, Ronday H, Kerstens P, Huizinga T, et al. Initial Combination Therapy in Early Rheumatoid Arthritis: Which Patients Benefit? Paper presented at the 2013 ACR\/ARHP Annual Meeting, San Diego, CA, 25\u201330 October 2013."},{"key":"key20181204135736878_ref1-bib628","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jbspin.2010.02.026","article-title":"Biomarkers for prediction of TNFalpha blockers response in rheumatoid arthritis","volume":"77","author":"Marotte","year":"2010","journal-title":"Joint Bone Spine"},{"key":"key20181204135736878_ref1-bib629","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/RHU.0000000000000152","article-title":"Older age at rheumatoid arthritis onset and comorbidities correlate with less Health Assessment Questionnaire-Disability Index and Clinical Disease Activity Index response to etanercept in the RADIUS 2 registry","volume":"20","author":"Martin","year":"2014","journal-title":"J Clin Rheumatol"},{"key":"key20181204135736878_ref1-bib630","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s00296-016-3506-3","article-title":"Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review","volume":"36","author":"Martin-Mola","year":"2016","journal-title":"Rheumatol Int"},{"key":"key20181204135736878_ref1-bib631","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1080\/14397595.2016.1227235","article-title":"Radiographic changes and factors associated with subsequent progression of damage in weight-bearing joints of patients with rheumatoid arthritis under TNF-blocking therapies. Three-year observational study","volume":"4","author":"Matsushita","year":"2017","journal-title":"Mod Rheumatol"},{"key":"key20181204135736878_ref1-bib632","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.3899\/jrheum.081096","article-title":"Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis","volume":"36","author":"Mattey","year":"2009","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib633","first-page":"S128\u2013S","article-title":"Analysis of the shared epitope and selected pro- and anti-inflammatory cytokine genes polymorphism as predictive factors of response to adalimumab in rheumatoid arthritis patients treated in the ReAct study","volume":"54","author":"Miceli-Richard","year":"2006","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib634","first-page":"509","article-title":"The association of body mass index with disease activity and clinical response to combination therapy in patients with rheumatoid arthritis","volume":"19","author":"Mirpourian","year":"2014","journal-title":"J Res Med Sci"},{"key":"key20181204135736878_ref1-bib635","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1136\/annrheumdis-2012-eular.448","article-title":"Factors leading to HAQ remission after beginning biologics treatment in patients with rheumatoid arthritis","volume":"71","author":"Miwa","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib636","first-page":"S627","article-title":"A novel method predicting good response using only background clinical data in RA patients treated with infliximab","volume":"65","author":"Miyoshi","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib637","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/acr.22542","article-title":"Association of socioeconomic status with treatment delays, disease activity, joint damage, and disability in rheumatoid arthritis","volume":"67","author":"Molina","year":"2015","journal-title":"Arthritis Care Res"},{"key":"key20181204135736878_ref1-bib638","first-page":"I31","article-title":"Does smoking predict poor response to anti-TNF therapy for rheumatoid arthritis?","volume":"46","author":"Moorthy","year":"2007","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib639","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/art.10135","article-title":"Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis","volume":"46","author":"M\u00f6tt\u00f6nen","year":"2002","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib640","first-page":"1852","article-title":"C-reactive protein levels correlate with functional outcome","volume":"24","author":"Munro","year":"1997","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib641","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s10165-008-0142-0","article-title":"Improvement of the HAQ score by infliximab treatment in patients with RA: its association with disease activity and joint destruction","volume":"19","author":"Nagasawa","year":"2009","journal-title":"Mod Rheumatol"},{"key":"key20181204135736878_ref1-bib642","doi-asserted-by":"publisher","first-page":"e0152362","DOI":"10.1371\/journal.pone.0152362","article-title":"A personalized approach to biological therapy using prediction of clinical response based on MRP8\/14 serum complex levels in rheumatoid arthritis patients","volume":"11","author":"Nair","year":"2016","journal-title":"PLOS ONE"},{"key":"key20181204135736878_ref1-bib643","first-page":"1118","article-title":"Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARD","volume":"62","author":"Narvaez","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib644","first-page":"991","article-title":"Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs","volume":"29","author":"Narvaez","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"key20181204135736878_ref1-bib645","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.semarthrit.2013.02.002","article-title":"Predictors and persistence of new-onset clinical remission in rheumatoid arthritis patients","volume":"43","author":"Navarro-Mill\u00e1n","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib646","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1007\/s10165-008-0089-1","article-title":"Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission","volume":"18","author":"Nawata","year":"2008","journal-title":"Mod Rheumatol"},{"key":"key20181204135736878_ref1-bib647","first-page":"S454\u2013S","article-title":"The prevalence of the ultrasonographic positive power Doppler synovitis is high and predicts the risk of relapse and structural progression in rheumatoid arthritis in clinical remission: a systematic literature review and meta analysis","volume":"64","author":"Nguyen","year":"2012","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib648","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1093\/rheumatology\/keu217","article-title":"Prevalence of ultrasound-detected residual synovitis and risk of relapse and structural progression in rheumatoid arthritis patients in clinical remission: a systematic review and meta-analysis","volume":"53","author":"Nguyen","year":"2014","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib649","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10165-013-0894-z","article-title":"Drug free REmission\/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study","author":"Nishimoto","year":"2013","journal-title":"Mod Rheumatol"},{"key":"key20181204135736878_ref1-bib650","article-title":"Ultrasound evaluation of the efficacy of biologic and targeted synthetic DMARDs toward rheumatoid arthritis patients: Kyushu multicenter rheumatoid arthritis ultrasound prospective observational cohort in japan","volume":"67","author":"Nishino","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib651","doi-asserted-by":"publisher","first-page":"A845","DOI":"10.1136\/annrheumdis-2013-eular.2518","article-title":"To develop a regression model for predicting damage-related HAQ: a nationwide study based on the NinJa (national database of rheumatic diseases by iR-net in Japan) 2011","volume":"72","author":"Nishiyama","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib652","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1002\/sim.2624","article-title":"Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis","volume":"26","author":"Nixon","year":"2007","journal-title":"Stat Med"},{"key":"key20181204135736878_ref1-bib653","article-title":"Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naive patients classified according to the 2010 ACR\/EULAR criteria","author":"Nordberg","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib654","article-title":"Titer of anti-citrullinated peptide antibody affects the efficacy of first biological treatment in rheumatoid arthritis","volume":"67","author":"Ogawa","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib655","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1136\/annrheumdis-2012-eular.513","article-title":"(F) good outcomes at week 24 is lead by early introduction of tocilizumab and favorable treatment response up to week 12","volume":"71","author":"Oguma","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib656","first-page":"S161","article-title":"Characteristic of the Japanese patients with rheumatoid arthritis (RA) of rapid radiographic progression (RRP) treated with synthetic disease modifying anti-rheumatic drugs (DMARDs) in daily practice: a large-scale prospective longitudinal cohort study (the 1st report of apple survey)","volume":"64","author":"Okada","year":"2012","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib657","doi-asserted-by":"publisher","first-page":"A203","DOI":"10.1136\/annrheumdis-2013-eular.649","article-title":"Characteristic of the Japanese patients with rheumatoid arthritis (RA) of rapid radiographic progression (RRP) treated with synthetic disease modifying anti-rheumatic drugs (DMARDs) in daily practice: a large-scale prospective longitudinal cohort study","volume":"72","author":"Okada","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib658","first-page":"S554","article-title":"Evaluation of the Japanese patients with rheumatoid arthritis (RA) of rapid radiographic progression (RRP) treated with synthetic disease modifying anti-rheumatic drugs (DMARDs) in daily practice: a large-scale prospective longitudinal cohort study (an interim report of Apple Survey)","volume":"65","author":"Okada","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib659","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-eular.4035","article-title":"Evaluation of the Japanese patients with rheumatoid arthritis (RA) of rapid radiographic progression (RRP) treated with synthetic disease modifying anti-rheumatic drugs (DMARDs) in daily practice: a large-scale prospective longitudinal cohort study","volume":"73","author":"Okada","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib660","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1136\/annrheumdis-2015-eular.6075","article-title":"Self-reported flares predict radiographic progression in rheumatoid arthritis patients in remission undergoing etanercept tapering","volume":"74","author":"Ometto","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib661","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/annrheumdis-2014-eular.3642","article-title":"The impacts of disease of the joints on modified health assessment questionnaire scores in rheumatoid arthritis patients: a retrospective study using the national database of rheumatic diseases by iR-net in Japan","volume":"73","author":"Ono","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib662","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/nrrheum.2012.71","article-title":"Rheumatoid arthritis. How bad is obesity for RA?","volume":"8","author":"Onuora","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"key20181204135736878_ref1-bib663","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1136\/annrheumdis-2014-eular.4812","article-title":"Serum drug level and anti-citrullinated peptide antibodies as biomarkers that predict EULAR response in rheumatoid arthritis-a new step to personalized medicine","volume":"73","author":"Opris","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib664","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1136\/annrheumdis-2015-eular.5684","article-title":"Active synovitis in rheumatoid arthritis patients while being on SDAI remission","volume":"74","author":"Opris","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib665","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/annrheumdis-2014-eular.4000","article-title":"Is there a difference in the effectiveness in the treatment of rheumatoid arthritis with rituximab in patients with rheumatoid factor positive and negative? A systematic review","volume":"73","author":"Ortiz","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib666","doi-asserted-by":"publisher","first-page":"A755","DOI":"10.1136\/annrheumdis-2013-eular.2238","article-title":"Associations between functional status and ultrasound-detected synovitis and joint damage in rheumatoid arthritis during tocilizumab treatment","volume":"72","author":"Osipyants","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib667","doi-asserted-by":"publisher","first-page":"A755","DOI":"10.1136\/annrheumdis-2013-eular.2237","article-title":"Imaging rather than clinical inflammation is associated with radiographic progression in tocilizumab-treated rheumatoid arthritis patients","volume":"72","author":"Osipyants","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib668","first-page":"478","article-title":"Body mass index and response to infliximab in rheumatoid arthritis","volume":"33","author":"Ottaviani","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"key20181204135736878_ref1-bib669","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1136\/annrheumdis-2015-eular.5501","article-title":"Work productivity in rheumatoid arthritis: analysis from a multicenter Turkish study","volume":"74","author":"Pamuk","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib670","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/RUQ.0b013e3181981df0","article-title":"Hypervascular synovitis and American College of Rheumatology Classification Criteria as predictors of radiographic damage in early rheumatoid arthritis","volume":"25","author":"Pascual-Ramos","year":"2009","journal-title":"Ultrasound Q"},{"key":"key20181204135736878_ref1-bib671","first-page":"19","article-title":"Prediction of radiographic progression of rheumatoid arthritis","volume":"18","author":"Pavelka","year":"2010","journal-title":"Ceska Revmatologie"},{"key":"key20181204135736878_ref1-bib672","doi-asserted-by":"publisher","first-page":"A2","DOI":"10.1136\/annrheumdis-2013-205124.4","article-title":"Predictive factors for the EULAR response in RA patients with rituximab treatment","volume":"73","author":"Peltea","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib673","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1136\/ard.2010.129924","article-title":"Clinical and ultrasonographic remission determines different chances of relapse in early and long standing rheumatoid arthritis","volume":"70","author":"Peluso","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib674","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1136\/annrheumdis-2012-eular.2091","article-title":"Multicenter retrospective study: response to tocilizumab in clinical practice is not influenced by the number of previous biotherapy or by association with a DMARD","volume":"71","author":"Pers","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib675","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/rheumatology\/ket301","article-title":"Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice","volume":"53","author":"Pers","year":"2014","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib676","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jbspin.2013.12.005","article-title":"TNFRII polymorphism is associated with response to TNF blockers in rheumatoid arthritis patients seronegative for ACPA","volume":"81","author":"Pers","year":"2014","journal-title":"Joint Bone Spine"},{"key":"key20181204135736878_ref1-bib677","doi-asserted-by":"publisher","first-page":"580","DOI":"10.3899\/jrheum.140673","article-title":"Response to tocilizumab in rheumatoid arthritis is not influenced by the body mass index of the patient","volume":"42","author":"Pers","year":"2015","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib678","article-title":"Baseline levels of the inflammatory biomarker C-reactive protein are significantly correlated with magnetic resonance imaging measures of synovitis at baseline and after 26 weeks of treatment in patients with early rheumatoid arthritis","volume":"63","author":"Peterfy","year":"2011","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib679","first-page":"1741","article-title":"Baseline levels of the inflammatory biomarker CRP are significantly correlated with MRI measures of synovitis at baseline and after 26 weeks of treatment in patients with early rheumatoid arthritis","volume":"39","author":"Peterfy","year":"2012","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib680","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1093\/rheumatology\/keh707","article-title":"What factors influence functional ability in patients with rheumatoid arthritis. Do they alter over time?","volume":"44","author":"Plant","year":"2005","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib681","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s10067-012-2146-6","article-title":"A predictive model for remission and low disease activity in patients with established rheumatoid arthritis receiving TNF blockers","volume":"32","author":"Pomirleanu","year":"2013","journal-title":"Clin Rheumatol"},{"key":"key20181204135736878_ref1-bib682","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3109\/03009742.2010.517548","article-title":"Does C-reactive protein add value in active rheumatoid arthritis? Results from the Optimization of Humira Trial","volume":"40","author":"Pope","year":"2011","journal-title":"Scand J Rheumatol"},{"key":"key20181204135736878_ref1-bib683","first-page":"S391","article-title":"High self-esteem is associated with low HAQ score in patients with rheumatoid arthritis","volume":"50","author":"Puolakka","year":"2004","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib684","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1093\/rheumatology\/kep314","article-title":"Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis","volume":"48","author":"Quartuccio","year":"2009","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib685","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s10067-016-3246-5","article-title":"Predictors of remission, erosive disease and radiographic progression in a Colombian cohort of early onset rheumatoid arthritis: a 3-year follow-up study","volume":"35","author":"Quintana-Duque","year":"2016","journal-title":"Clin Rheumatol"},{"key":"key20181204135736878_ref1-bib686","first-page":"336","article-title":"Influence of age and gender on the interpretation of the Disease Activity Score-28 (DAS28) in rheumatoid arthritis","volume":"66","author":"Radovits","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib687","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1093\/rheumatology\/kev301","article-title":"Elevated baseline power Doppler discriminates an RA subgroup highly responsive to therapy","volume":"54","author":"Ranganath","year":"2015","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib688","article-title":"Vitality, presenteeism, and their determinants in patients with early rheumatoid arthritis treated with a 6-month induction infliximab therapy added on a triple combination therapy","volume":"67","author":"Rantalaiho","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib689","doi-asserted-by":"publisher","first-page":"A153","DOI":"10.1016\/j.jval.2015.03.889","article-title":"Factors and reasons associated with switching in rheumatoid arthritis patients newly initiated on biologic DMARDs and impact on health care resource utilization in a managed care organization","volume":"18","author":"Rashid","year":"2015","journal-title":"Value Health"},{"key":"key20181204135736878_ref1-bib690","doi-asserted-by":"publisher","first-page":"A153","DOI":"10.1016\/j.jval.2015.03.888","article-title":"Factors and reasons associated with switching in rheumatoid arthritis patients experienced on biologic DMARDs and impact on health care resource utilization in an integrated healthcare system","volume":"18","author":"Rashid","year":"2015","journal-title":"Value Health"},{"key":"key20181204135736878_ref1-bib691","first-page":"1637","article-title":"Prediction of disease relapses by multi-biomarker disease test activity in rheumatoid arthritis patients tapering DMARD treatment","volume":"75","author":"Rech","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib692","doi-asserted-by":"publisher","first-page":"A449","DOI":"10.1136\/annrheumdis-2013-eular.1351","article-title":"Predictive factors of response to tocilizumab in patients with active rheumatoid arthritis","volume":"72","author":"Reina","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib693","first-page":"259","article-title":"Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying antirheumatic drug","volume":"26","author":"Rich","year":"1999","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib694","first-page":"S402","article-title":"Clinical and ultrasonographic assessment of evolution in patients with rheumatoid arthritis treated with tocilizumab","volume":"22","author":"Rkain","year":"2011","journal-title":"Osteoporos Int"},{"key":"key20181204135736878_ref1-bib695","doi-asserted-by":"publisher","first-page":"A1","DOI":"10.1136\/annrheumdis-2013-205124.1","article-title":"Obesity is a risk factor for worse treatment response in rheumatoid arthritis patients \u2013 results from reuma.pt","volume":"73","author":"Rodrigues","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib696","doi-asserted-by":"publisher","first-page":"A76","DOI":"10.1136\/annrheumdis-2015-eular.3399","article-title":"Clinical and pathological differences of elderly- and younger-onset rheumatoid arthritis in an early arthritis cohort","volume":"74","author":"Romao","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib697","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/BF00290376","article-title":"Antineutrophil cytoplasmic antibodies (ANCA) in rheumatoid arthritis: a prospective study","volume":"15","author":"R\u00f6ther","year":"1996","journal-title":"Rheumatol Int"},{"key":"key20181204135736878_ref1-bib698","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.3899\/jrheum.110410","article-title":"Effects of smoking on disease activity and radiographic progression in early rheumatoid arthritis","volume":"38","author":"Ruiz-Esquide","year":"2011","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib699","first-page":"1714","article-title":"Efficacy with abatacept in patients with earlier versus more longstanding disease: Insights from the AIM trial","volume":"39","author":"Russell","year":"2012","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib700","first-page":"228","article-title":"Predicting response to treatment in patients with rheumatoid arthritis","volume":"6","author":"Saevarsdottir","year":"2011","journal-title":"European Musculoskeletal Review"},{"key":"key20181204135736878_ref1-bib701","first-page":"S897","article-title":"Predictive value of anti-CCP positivity on disease course and response to therapy in early rheumatoid arthritis. Results from the Swedish EIRA study","volume":"64","author":"Saevarsdottir","year":"2012","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib702","first-page":"S1095","article-title":"Long-term treatment with tocilizumab (TCZ) strongly suppresses joint destruction in biologic-naive patients with rheumatoid arthritis (RA) regardless of inflammation status","volume":"66","author":"Sagawa","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib703","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1111\/1756-185X.12443","article-title":"IgA rheumatoid factor as a serological predictor of poor response to tumour necrosis factor \u03b1 inhibitors in rheumatoid arthritis","volume":"17","author":"Sakthiswary","year":"2014","journal-title":"Int J Rheum Dis"},{"key":"key20181204135736878_ref1-bib704","unstructured":"Salgado E, Maneiro JR, Carmona L, Gomez-Reino JJ. Influence of Baseline Rheumatoid Factor on the Response to Tumor Necrosis Factor Antagonists of Rheumatoid Arthritis Patients: a Systematic Review and Meta-Analysis. American College of Rheumatology\/Association of Rheumatology Health Professionals (ACR\/ARHP) Annual Scientific Meeting, Chicago, IL, 4\u20139 November 2011."},{"key":"key20181204135736878_ref1-bib705","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1136\/annrheumdis-2012-eular.279","article-title":"Rheumatoid factor and response to TNF antagonists in rheumatoid arthritis: systematic review and meta-analysis of observational studies","volume":"71","author":"Salgado","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib706","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jbspin.2013.01.004","article-title":"Rheumatoid factor does not predict response to TNF antagonists in rheumatoid arthritis: three centers experience","volume":"80","author":"Salgado","year":"2013","journal-title":"Joint Bone Spine"},{"key":"key20181204135736878_ref1-bib707","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1136\/annrheumdis-2012-eular.278","article-title":"The effect of rheumatoid factor titer on the response to TNF antagonists","volume":"71","author":"Salgado","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib708","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jbspin.2013.04.004","article-title":"Rheumatoid factor and response to TNF antagonists in rheumatoid arthritis: systematic review and meta-analysis of observational studies (provisional abstract)","volume":"81","author":"Salgado","year":"2014","journal-title":"Joint Bone Spine"},{"key":"key20181204135736878_ref1-bib709","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2174\/1381612820666140825124152","article-title":"Predictors of response to TNF antagonists","volume":"21","author":"Salgado","year":"2015","journal-title":"Curr Pharm Des"},{"key":"key20181204135736878_ref1-bib710","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1093\/rheumatology\/keg284","article-title":"Radiological progression in early rheumatoid arthritis after DMARDS: a one-year follow-up study in a clinical setting","volume":"42","author":"Sanmart\u00ed","year":"2003","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib711","first-page":"S1299","article-title":"The multi-biomarker disease activity score as a predictor of radiographic progression in a registry of patients with rheumatoid arthritis","volume":"66","author":"Sasso","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib712","first-page":"280","article-title":"Effectiveness and costs of biologics in veterans with rheumatoid arthritis","volume":"7","author":"Sauer","year":"2015","journal-title":"Am J Pharm Benefits"},{"key":"key20181204135736878_ref1-bib713","article-title":"High body mass index negatively impacts time to achieving sustained remission in early rheumatoid arthritis: results from a multicenter early arthritis cohort study","volume":"67","author":"Schulman","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib714","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1136\/annrheumdis-2014-eular.3855","article-title":"Therapeutic response to tocilizumab in rheumatoid arthritis: does body weight have an influence?","volume":"73","author":"Segaud","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib715","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1136\/annrheumdis-2015-eular.2693","article-title":"Predicting factors associated with sustained clinical remission by abatacept are different between in younger and elderly patients with biologic-naive rheumatoid arthritis (ABROAD study)","volume":"74","author":"Sekiguchi","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib716","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.3899\/jrheum.160051","article-title":"Differences in predictive factors for sustained clinical remission with abatacept between younger and elderly patients with biologic-naive rheumatoid arthritis: results from the ABROAD study","volume":"43","author":"Sekiguchi","year":"2016","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib717","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/art.30233","article-title":"B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study","volume":"63","author":"Sellam","year":"2011","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib718","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1136\/annrheumdis-2015-eular.5305","article-title":"Lifestyle, clinical and psychosocial predictors of good response to methotrexate therapy in the rheumatoid arthritis medication study (RAMS)","volume":"74","author":"Sergeant","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib719","first-page":"1041","article-title":"Serum anti-CCP antibody and its correlation with disease activity in local Pakistani rheumatoid arthritis patients","volume":"8","author":"Shah","year":"2014","journal-title":"Pak J Med Health Sci"},{"key":"key20181204135736878_ref1-bib720","first-page":"S418","article-title":"Biologic de-escalation in rheumatoid arthritis: cost savings and clinical success","volume":"66","author":"Sharma","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib721","first-page":"705","article-title":"Disability in rheumatoid arthritis: comparison of prognostic factors across three populations","volume":"14","author":"Sherrer","year":"1987","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib722","doi-asserted-by":"publisher","first-page":"A839","DOI":"10.1136\/annrheumdis-2013-eular.2499","article-title":"MMP-3 as a predictor that identifies a subgroup with potential radiographic progression requiring additional biologics to halt future progression among the rheumatoid arthritis patients succeedingly treated with methotrexate (MTX) alone","volume":"72","author":"Shiozawa","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib723","first-page":"i103","article-title":"Effect of body mass index on clinical response to anti-TNF therapies in rheumatoid arthritis: a retrospective study","volume":"52","author":"Shrestha","year":"2013","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib724","doi-asserted-by":"publisher","first-page":"A399","DOI":"10.1136\/annrheumdis-2013-eular.1215","article-title":"Effect of body mass index on clinical response to anti-TNF therapy in rheumatoid arthritis","volume":"72","author":"Shrestha","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib725","first-page":"1534","article-title":"Impact of missing anti-cyclic citrullinated peptide (CCP) antibody serology on clinical outcomes in early rheumatoid arthritis: results from catch (Canadian early arthritis cohort)","volume":"41","author":"Shu","year":"2014","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib726","first-page":"iii124","article-title":"Abatacept confers clinical efficacy regardless of baseline CRP status in patients with rheumatoid arthritis and inadequate response to methotrexate in the aim trial","volume":"51","author":"Sibilia","year":"2012","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib727","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1136\/annrheumdis-2014-eular.4272","article-title":"Genetic and clinical predictors of response to TNF-alpha therapy in an Italian axial-SPA cohort","volume":"73","author":"Simone","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"(5)","key":"key20181204135736878_ref1-bib728","first-page":"802","article-title":"Genetic and clinical predictors of response to TNF blocker in an Italian axial-SPA cohort","volume":"32","author":"Simone","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"key20181204135736878_ref1-bib729","doi-asserted-by":"publisher","first-page":"A875","DOI":"10.1136\/annrheumdis-2013-eular.2611","article-title":"Can CD11C expression successfully predict response to etanercept in rheumatoid arthritis patients?","volume":"72","author":"Smith","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib730","article-title":"Baseline predictors of remission with combination etanercept-methotrexate therapy in moderately active rheumatoid arthritis: Interim results of the preserve trial","volume":"63","author":"Smolen","year":"2011","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib731","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1136\/annrheumdis-2011-200395","article-title":"Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction","volume":"71","author":"Smolen","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib732","article-title":"The effect of prior disease duration and prior DMARD use on treatment outcomes in patients with early or established rheumatoid arthritis","volume":"67","author":"Smolen","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib733","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1756-185X.2009.01412.x","article-title":"Prevalence of anti cyclic citrullinated peptide antibodies in Malaysian rheumatoid arthritis patients and its correlation with disease activity","volume":"12","author":"Sockalingam","year":"2009","journal-title":"Int J Rheum Dis"},{"key":"key20181204135736878_ref1-bib734","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.3899\/jrheum.100991","article-title":"Absent \u2018Window of Opportunity\u2019 in smokers with short disease duration. Data from BARFOT, a multicenter study of early rheumatoid arthritis","volume":"38","author":"S\u00f6derlin","year":"2011","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib735","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/03009742.2011.599073","article-title":"The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug","volume":"41","author":"S\u00f6derlin","year":"2012","journal-title":"Scand J Rheumatol"},{"key":"key20181204135736878_ref1-bib736","first-page":"122","article-title":"Second-hand exposure to tobacco smoke and its effect on disease activity in Swedish rheumatoid arthritis patients. Data from BARFOT, a multicenter study of RA","volume":"31","author":"S\u00f6derlin","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"key20181204135736878_ref1-bib737","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/1529-0131(200002)43:2<386::AID-ANR19>3.0.CO;2-Z","article-title":"Scores for functional disability in patients with rheumatoid arthritis are correlated at higher levels with pain scores than with radiographic scores","volume":"43","author":"Sokka","year":"2000","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib738","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jbspin.2011.05.002","article-title":"Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, coprescription of methotrexate and prior TNF-alpha inhibitors exposure","volume":"79","author":"Solau-Gervais","year":"2012","journal-title":"Joint Bone Spine"},{"key":"key20181204135736878_ref1-bib739","doi-asserted-by":"publisher","first-page":"iii111","DOI":"10.1093\/rheumatology\/ker073","article-title":"Predictors of response to rituximab in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"50","author":"Soliman","year":"2011","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib740","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1136\/annrheumdis-2012-eular.495","article-title":"Functional outcome in response to treatment with DMARDs compared to anti-TNF agents in a cohort with rheumatoid arthritis","volume":"71","author":"Srirangan","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib741","first-page":"S1019","article-title":"A useful mathematical model able to predict the early response to tocilizumab in rheumatoid arthritis","volume":"65","author":"Stagnaro","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib742","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1136\/ard.2006.060319","article-title":"Redefining overweight and obesity in rheumatoid arthritis patients","volume":"66","author":"Stavropoulos-Kalinoglou","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib743","article-title":"Superiority of initial combination-over step up therapy in treatment to the target of remission in daily clinical practice in early rheumatoid arthritis patients: results from the DREAM registry","volume":"67","author":"Steunebrink","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib744","first-page":"S777","article-title":"Factors that impact work productivity in the preserve trial: a randomized controlled trial of combination etanercept\u2013methotrexate therapy in patients with moderately active rheumatoid arthritis","volume":"64","author":"Strand","year":"2012","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib745","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1136\/annrheumdis-2012-eular.1385","article-title":"Predictors of work impairment in a randomized controlled trial of etanercept\u2013methotrexate therapy in patients with moderate rheumatoid arthritis","volume":"71","author":"Strand","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib746","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2217\/ijr.15.40","article-title":"The impact of rheumatoid arthritis on work and predictors of overall work impairment from three therapeutic scenarios","volume":"10","author":"Strand","year":"2015","journal-title":"Int J Clin Rheumatol"},{"key":"key20181204135736878_ref1-bib747","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1136\/annrheumdis-2015-eular.1603","article-title":"Analysis of the association between cigarette smoking and clinical response to certolizumab pegol treatment in Hungarian patients with rheumatoid arthritis","volume":"74","author":"Szekanecz","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib748","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1136\/annrheumdis-2012-eular.3088","article-title":"Predictive factors for radiographic progression in low- and standard-dose etanercept therapy for rheumatoid arthritis from the prevention of cartilage destruction by etanercept (precept) study","volume":"71","author":"Tada","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib749","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/rheumatology\/ker300","article-title":"A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm","volume":"51","author":"Tak","year":"2012","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib750","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1093\/rheumatology\/ker221","article-title":"Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients \u2013 REACTION 52-week study","volume":"50","author":"Takeuchi","year":"2011","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib751","first-page":"S1102","article-title":"Analysis on predictors for long-term clinical efficacies of golimumab in patients with rheumatoid arthritis","volume":"66","author":"Takeuchi","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib752","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1136\/annrheumdis-2014-eular.2192","article-title":"Impact of disease duration before starting adalimumab treatment on work productivity in Japanese patients with rheumatoid arthritis; analysis of 24-weeks data from the ANOUVEAU study","volume":"73","author":"Takeuchi","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib753","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s10067-006-0372-5","article-title":"Rapid improvement in rheumatoid arthritis patients on combination of methotrexate and infliximab: clinical and magnetic resonance imaging evaluation","volume":"26","author":"Tam","year":"2007","journal-title":"Clin Rheumatol"},{"key":"key20181204135736878_ref1-bib754","first-page":"S906","article-title":"Magnetic resonance imaging-proven osteitis at baseline predicts the early rheumatoid arthritis patients who will develop rapid radiographic progression: MRI is beneficial to find the window of opportunity in early RA","volume":"64","author":"Tamai","year":"2012","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib755","first-page":"S183","article-title":"Investigation of MRI bone changes in early-stage RA patients achieved in sustained clinical good response: sub-analysis from Nagasaki University early arthritis cohort","volume":"66","author":"Tamai","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib756","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1136\/ard.2007.072751","article-title":"Efficient management of rheumatoid arthritis significantly reduces long-term functional disability","volume":"67","author":"Tanaka","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib757","first-page":"S570\u2013S1","article-title":"Prevention of joint destruction in patients with high disease activity or high C-reactive protein","volume":"64","author":"Tanaka","year":"2012","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib758","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s10165-011-0510-z","article-title":"Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept","volume":"22","author":"Tanaka","year":"2012","journal-title":"Mod Rheumatol"},{"key":"key20181204135736878_ref1-bib759","doi-asserted-by":"publisher","first-page":"A453","DOI":"10.1136\/annrheumdis-2013-eular.1363","article-title":"Efficacy and safety of tocilizumab therapy in rheumatoid arthritis: prevalence and predictive factors of sustained remission","volume":"72","author":"Tanaka","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib760","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1136\/annrheumdis-2015-eular.3665","article-title":"A longitudinal study of factors contributing to the worsening of absenteeism in patients with rheumatoid arthritis based on the IORRA cohort","volume":"74","author":"Tanaka","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib761","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3109\/14397595.2015.1086041","article-title":"Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels: post hoc analysis of the GO-FORTH study","volume":"26","author":"Tanaka","year":"2016","journal-title":"Mod Rheumatol"},{"key":"key20181204135736878_ref1-bib762","article-title":"Predicting the need for additional treatment in early rheumatoid arthritis patients treated to target on methotrexate monotherapy","volume":"67","author":"Teitsma","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib763","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1002\/art.39306","article-title":"Rheumatoid factor is associated with the distribution of hand joint destruction in rheumatoid arthritis","volume":"67","author":"Terao","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib764","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/acr.22290","article-title":"Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registry","volume":"66","author":"Thorne","year":"2014","journal-title":"Arthritis Care Res"},{"key":"key20181204135736878_ref1-bib765","first-page":"1582","article-title":"Analysis of the association of CDA (cytidin deaminase) (K27Q), TNF-(\u2013308G>A) and PTPN22 R620W genetic polymorphisms with auto-antibody seropositive RA and the response to B cell depletion","volume":"62","author":"Tolusso","year":"2010","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib766","first-page":"292","article-title":"Predictive factors for response to rituximab in patients with rheumatoid arthritis (FIRST)","volume":"70","author":"Tony","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib767","first-page":"S203","article-title":"Assessment of 12-month efficacy and safety of 168 certolizumab pegol rheumatoid arthritis treated patients from a multicenter retrospective national study in Spain","volume":"66","author":"Torrente-Segarra","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib768","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3109\/14397595.2015.1101200","article-title":"RENACER study: assessment of 12-month efficacy and safety of 168 certolizumab pegol rheumatoid arthritis-treated patients from a Spanish multicenter national database","volume":"26","author":"Torrente-Segarra","year":"2015","journal-title":"Mod Rheumatol"},{"key":"key20181204135736878_ref1-bib769","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3899\/jrheum.110584","article-title":"IgG glycosylation changes and MBL2 polymorphisms: associations with markers of systemic inflammation and joint destruction in rheumatoid arthritis","volume":"39","author":"Troelsen","year":"2012","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib770","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1136\/annrheumdis-2014-eular.2437","article-title":"Baseline procalcitonin (PCT) level as a predictive marker for clinical remission (DAS28-ESR, CDAI) at 52 weeks in biologic naive rheumatoid arthritis (RA) patients treated by tocilizumab (TCZ); a single center retrospective study","volume":"73","author":"Tsuji","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib771","doi-asserted-by":"publisher","first-page":"R8","DOI":"10.1186\/ar2907","article-title":"Levels of anti-citrullinated protein antibodies and IgM rheumatoid factor are not associated with outcome in early arthritis patients: a cohort study","volume":"12","author":"Ursum","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"key20181204135736878_ref1-bib772","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1136\/annrheumdis-2011-200379","article-title":"The association of treatment response and joint damage with ACPA-status in recent-onset RA: a subanalysis of the 8-year follow-up of the BeSt study","volume":"71","author":"van den Broek","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib773","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.coph.2013.03.006","article-title":"Personalized medicine: predicting responses to therapy in patients with RA","volume":"13","author":"van den Broek","year":"2013","journal-title":"Curr Opin Pharmacol"},{"key":"key20181204135736878_ref1-bib774","first-page":"436","article-title":"Baseline CRP concentrations predict radiographic progression in MTX-naive patients with early RA: subanalysis of the PREMIER study","volume":"58648","author":"van der Heijde","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib775","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1136\/ard.2007.078832","article-title":"A high body mass index has a protective effect on the amount of joint destruction in small joints in early rheumatoid arthritis","volume":"67","author":"van der Helm-van Mil","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib776","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.3899\/jrheum.110928","article-title":"Inclusion criteria based on DAS28 score: strength of improvement is less dependent on baseline disease activity than expected","volume":"38","author":"van der Horst-Bruinsma I","year":"2011","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib777","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1136\/annrheumdis-2014-eular.2337","article-title":"Validity of OMERACT preliminary flare questions in a randomized controlled trial, that assesses impact of disease activity guided down-titration of anti-TNF treatment in rheumatoid arthritis patients in low disease activity","volume":"73","author":"Van Der Maas","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib778","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1002\/art.24661","article-title":"Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts","volume":"60","author":"van der Woude","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib779","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1002\/art.20316","article-title":"Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis","volume":"50","author":"van Gaalen","year":"2004","journal-title":"Arthritis Rheum"},{"key":"key20181204135736878_ref1-bib780","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/ncprheum0596","article-title":"Do high levels of IgA rheumatoid factor indicate a poor response to treatment with TNF inhibitors in patients with RA?","volume":"3","author":"van Laar","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"key20181204135736878_ref1-bib781","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1136\/annrheumdis-2012-203130","article-title":"What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review","volume":"73","author":"van Nies","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib782","first-page":"S1016","article-title":"A novel and effective prediction model of response to rituximab in rheumatoid arthritis","volume":"65","author":"Van Sijl","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib783","first-page":"1671","article-title":"Six-month results from the collaborative European registries for rituximab in rheumatoid arthritis (cererra). Efficacy of rituximab is highest in RF-positive patients and in those who failed at most one prior anti-TNF","volume":"60","author":"Van Vollenhoven","year":"2009","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib784","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206383","article-title":"A prediction model that identifies patients most likely to benefit from first-line therapy with adalimumab plus methotrexate in early rheumatoid arthritis","volume":"73","author":"Van Vollenhoven","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib785","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1093\/rheumatology\/kew179","article-title":"Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab","volume":"55","author":"Vastesaeger","year":"2016","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib786","first-page":"231","article-title":"Prognostic markers of clinical remission in early rheumatoid arthritis after two years of DMARDs in a clinical setting","volume":"25","author":"V\u00e1zquez","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"key20181204135736878_ref1-bib787","doi-asserted-by":"crossref","first-page":"A32","DOI":"10.1136\/annrheumdis-2013-203219.8","article-title":"B cell depletion therapy in a cohort of patients with seropositive and seronegative rheumatoid arthritis","volume":"72","author":"Velloso Feijoo","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib788","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/annrheumdis-2014-eular.2012","article-title":"Can we use ultrasound to identify rheumatoid arthritis patients in remission who can taper their medication?","volume":"73","author":"Ven","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib789","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1080\/03009740802484846","article-title":"Predictors of remission, normalized physical function, and changes in the working situation during followup of patients with early rheumatoid arthritis an observational study","volume":"38","author":"Verschueren","year":"2009","journal-title":"Scand J Rheumatol"},{"key":"key20181204135736878_ref1-bib790","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/rheumatology\/keh400","article-title":"Working status among Dutch patients with rheumatoid arthritis: work disability and working conditions","volume":"44","author":"Verstappen","year":"2005","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib791","first-page":"1617","article-title":"Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate (the CAMERA study)","volume":"60","author":"Verstappen","year":"2009","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib792","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1093\/rheumatology\/keq131","article-title":"Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register","volume":"49","author":"Verstappen","year":"2010","journal-title":"Rheumatology"},{"key":"key20181204135736878_ref1-bib793","first-page":"S167","article-title":"Influence of body mass index on disease activity and radiographic joint damage in rheumatoid arthritis: a systematic review and meta-analysis","volume":"66","author":"Vidal","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib794","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.3899\/jrheum.101283","article-title":"Effect of the application of trial inclusion criteria on the efficacy of adalimumab therapy in a rheumatoid arthritis cohort","volume":"38","author":"Visman","year":"2011","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib795","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1136\/ard.2008.088070","article-title":"Pretreatment serum levels of anti-cyclic citrullinated peptide antibodies are associated with the response to methotrexate in recent-onset arthritis","volume":"67","author":"Visser","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib796","first-page":"1126","article-title":"Serum cytokine profile predicts response to rituximab therapy in rheumatoid arthritis","volume":"62","author":"Vital","year":"2010","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib797","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1136\/annrheumdis-2012-eular.1915","article-title":"Monitoring anti-interleukin 6 receptor antibody treatment in rheumatoid arthritis and prediction progressive structural damage of the wrist joints by ultrasonography","volume":"71","author":"Volkov","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib798","first-page":"673","article-title":"Subclinical ultrasound synovitis in a particular joint is associated with ultrasound evidence of bone erosions in that same joint in rheumatoid patients in clinical remission","volume":"34","author":"Vreju","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"key20181204135736878_ref1-bib799","first-page":"S620","article-title":"Serum markers associated with clinical response in methotrexate na\u00efve rheumatoid arthritis patients treated with golimumab, a human anti-TNF\u03b1 monoclonal antibody","volume":"60","author":"Wagner","year":"2009","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib800","first-page":"532","article-title":"Association of serum markers with clinical response measures in rheumatoid arthritis patients treated with golimumab, a human anti-TNF alpha monoclonal antibody","volume":"69","author":"Wagner","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib801","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/jcph.668","article-title":"Short-term efficacy reliably predicts long-term clinical benefit in rheumatoid arthritis clinical trials as demonstrated by model-based meta-analysis","volume":"56","author":"Wang","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"key20181204135736878_ref1-bib802","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/acr.22765","article-title":"Relationship between baseline and early changes in C-reactive protein and interleukin-6 levels and clinical response to tocilizumab in rheumatoid arthritis","volume":"68","author":"Wang","year":"2016","journal-title":"Arthritis Care Res"},{"key":"key20181204135736878_ref1-bib803","first-page":"S1012","article-title":"Tocilizumab efficiently halts radiographic progression in patients with rheumatoid arthritis and swollen joint counts within a year predict long-term radiographic outcomes: three year results from Michinoku Tocilizumab Study Group","volume":"65","author":"Watanabe","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib804","first-page":"S181","article-title":"Predictors of poor radiographic response in rheumatoid arthritis subjects treated with methotrexate: preliminary analysis from the ERA and TEMPO studies","volume":"54","author":"Weinblatt","year":"2006","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib805","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3899\/jrheum.091446","article-title":"Factors associated with radiographic progression in patients with rheumatoid arthritis who were treated with methotrexate","volume":"38","author":"Weinblatt","year":"2011","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib806","doi-asserted-by":"publisher","first-page":"A81","DOI":"10.1136\/annrheumdis-2013-eular.297","article-title":"Indicators of depression are stronger predictors of work disability in early arthritis than disease activity or response to therapy","volume":"72","author":"Westhoff","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib807","article-title":"Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis","volume":"63","author":"Wevers-De Boer","year":"2011","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib808","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1136\/annrheumdis-2011-200736","article-title":"Extended report: remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study)","volume":"71","author":"Wevers-De Boer","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib809","first-page":"S172","article-title":"Remission after one year in ACPA positive and ACPA negative patients with early arthritis","volume":"64","author":"Wevers-De Boer","year":"2012","journal-title":"Arthritis Rheumatol"},{"key":"key20181204135736878_ref1-bib810","doi-asserted-by":"publisher","first-page":"A549","DOI":"10.1136\/annrheumdis-2013-eular.1644","article-title":"Early metacarpal bone mineral density loss is predictive for radiologic joint damage progression after 1 year in patients with early arthritis","volume":"72","author":"Wevers-De Boer","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib811","first-page":"A74","article-title":"Clinical features of disease severity and body mass index predict outcome at 6 months in a cohort of patients with early rheumatoid arthritis","volume":"39","author":"White","year":"2009","journal-title":"Intern Med"},{"key":"key20181204135736878_ref1-bib812","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/acr.21627","article-title":"Effect of body mass index on mortality and clinical status in rheumatoid arthritis","volume":"64","author":"Wolfe","year":"2012","journal-title":"Arthritis Care Res"},{"key":"key20181204135736878_ref1-bib813","doi-asserted-by":"publisher","first-page":"A210","DOI":"10.1136\/annrheumdis-2013-eular.668","article-title":"Plasma adiponectin level and body mass index (BMI) predict response to treatment in patients with rheumatoid arthritis","volume":"72","author":"Xibille","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib814","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2012-eular.3033","article-title":"Leptin and adiponectin serum levels as predictors of treatment response in patients with rheumatoid arthritis","volume":"71","author":"Xibille","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib815","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s10165-006-0532-0","article-title":"Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM)","volume":"17","author":"Yamanaka","year":"2007","journal-title":"Mod Rheumatol"},{"key":"key20181204135736878_ref1-bib816","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3109\/14397595.2014.994263","article-title":"Trend of patient characteristics and its impact on the response to adalimumab in patients with rheumatoid arthritis: post hoc time-course analysis of an all-case PMS in Japan","volume":"25","author":"Yamanaka","year":"2015","journal-title":"Mod Rheumatol"},{"key":"key20181204135736878_ref1-bib817","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1136\/annrheumdis-2014-eular.4147","article-title":"Predictive marker for the long-term discontinuation of infliximab in rheumatoid arthritis with clinical remission","volume":"73","author":"Yamasaki","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib818","first-page":"494","article-title":"Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data","volume":"29","author":"Yazici","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"key20181204135736878_ref1-bib819","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.3899\/jrheum.150240","article-title":"Incidence and predictors of biological antirheumatic drug discontinuation attempts among patients with rheumatoid arthritis in remission: a CORRONA and NinJa collaborative cohort study","volume":"42","author":"Yoshida","year":"2015","journal-title":"J Rheumatol"},{"key":"key20181204135736878_ref1-bib820","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/s10165-012-0690-1","article-title":"Ultrasonography is a potent tool for the prediction of progressive joint destruction during clinical remission of rheumatoid arthritis","volume":"23","author":"Yoshimi","year":"2013","journal-title":"Mod Rheumatol"},{"key":"key20181204135736878_ref1-bib821","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2152\/jmi.60.77","article-title":"Treatment responses and their predictors in patients with rheumatoid arthritis treated with biological agents","volume":"60","author":"Yuasa","year":"2013","journal-title":"J Med Invest"},{"key":"key20181204135736878_ref1-bib822","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1136\/annrheumdis-2012-202480","article-title":"Reply to: very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study","volume":"71","author":"Zeidler","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib823","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1136\/ard.2008.092460","article-title":"The sensitivity to change for lower disease activity is greater than for higher disease activity in rheumatoid arthritis trials","volume":"68","author":"Zhang","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key20181204135736878_ref1-bib824","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.3892\/etm.2014.2001","article-title":"Application of high frequency color Doppler ultrasound in the monitoring of rheumatoid arthritis treatment","volume":"8","author":"Zheng","year":"2014","journal-title":"Exp Ther Med"},{"key":"key20181204135736878_ref1-bib825","unstructured":"Zhilyaev EV. Efficacy of Biological Treatment in Cohort of Rheumatoid Arthritis Patients in Moscow. 2nd Bio-Rheumatology International Congress (BRIC) and the 9th Global Arthritis Research Network (GARN), Moscow, Russian Federation, 5\u20137 June 2014."},{"key":"key20181204135736878_ref1-bib826","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jbspin.2012.05.003","article-title":"Disease activity in rheumatoid arthritis patients at initiation of biologic agents and 1 year of treatment: results from the Swiss SCQM registry","volume":"80","author":"Zufferey","year":"2013","journal-title":"Joint Bone Spine"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta22660\/hta22660.xml","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2003433","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta22660\/hta22660.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2021629","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T08:20:48Z","timestamp":1775290848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta22660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":826,"journal-issue":{"issue":"66","published-online":{"date-parts":[[2018,11]]}},"alternative-id":["10.3310\/hta22660"],"URL":"https:\/\/doi.org\/10.3310\/hta22660","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"}]}}